{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:19:41Z","timestamp":1793315981258,"version":"4.5.0"},"reference-count":288,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>High-grade serous ovarian cancer (HGSOC) is often diagnosed at advanced stages (III\/IV), with approximately 80% of patients experiencing relapse due to therapeutic resistance. The disease progression is largely influenced by a dynamic tumor microenvironment (TME), which is marked by sustained inflammation, immune evasion, and epigenetic reprogramming. This review investigates the dual role of inflammatory pathways and epigenetic alterations in driving HGSOC progression and chemo-resistance. A comprehensive literature search of articles from 2000 to 2025 was conducted across PubMed, Google Scholar, and Research Rabbit using search terms including \u201cHGSOC,\u201d \u201cepigenetics,\u201d \u201cinflammation,\u201d and \u201cchemoresistance.\u201d Of 1,166 identified publications, 593 peer-reviewed studies comprising original research, clinical trials, meta-analyses, and reviews were critically analyzed. Findings reveal that chronic inflammation in the TME enhances tumor proliferation, immune suppression, epithelial-mesenchymal transition, and metastasis through cytokines, interferons, and chemokines. Epigenetic mechanisms such as DNA methylation, histone modifications, miRNA and lncRNA contribute to tumor plasticity and treatment failure. Emerging therapies, including histone deacetylase inhibitors, DNA methyltransferase inhibitors, and immune checkpoint inhibitors, anti-inflammatory drugs demonstrate potential in overcoming resistance when used in combination. Integrative treatment strategies that target both inflammatory signaling and epigenetic dysregulation offer a promising avenue for improving patient outcomes. Further clinical exploration of such combination therapies is warranted to address the urgent need for effective interventions in HGSOC.<\/jats:p>","DOI":"10.1186\/s13148-026-02080-6","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:13:20Z","timestamp":1770880400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inflammatory milieu and role of epigenetic modifications in high-grade serous ovarian cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Satarupa","family":"Pradhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shama Prasada","family":"Kabekkodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangavi","family":"Eswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveena A. N.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Upadhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiban","family":"Chakrabarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0292-6352","authenticated-orcid":false,"given":"Vasudha","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"1","key":"2080_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"2080_CR2","unstructured":"SEER*Explorer Application [Internet]. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=61&data_type=1&graph_type=2&compareBy=race&chk_race_6=6&chk_race_5=5&chk_race_4=4&chk_race_9=9&chk_race_8=8&rate_type=2&hdn_sex=3&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0;Accessed 16 July 2025;"},{"issue":"3","key":"2080_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237\u201349. https:\/\/doi.org\/10.1007\/s00428-012-1203-5.","journal-title":"Virchows Arch"},{"issue":"10","key":"2080_CR4","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/s12276-023-01090-1","volume":"55","author":"H Machino","year":"2023","unstructured":"Machino H, Dozen A, Konaka M, Komatsu M, Nakamura K, Ikawa N, et al. Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas. Exp Mol Med. 2023;55(10):2205\u201319. https:\/\/doi.org\/10.1038\/s12276-023-01090-1.","journal-title":"Exp Mol Med"},{"issue":"23","key":"2080_CR5","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.3390\/cancers13235993","volume":"13","author":"BG Matthews","year":"2021","unstructured":"Matthews BG, Bowden NA, Wong-Brown MW. Epigenetic mechanisms and therapeutic targets in chemoresistant high-grade serous ovarian cancer. Cancers (Basel). 2021;13(23):5993. https:\/\/doi.org\/10.3390\/cancers13235993.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2080_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00404-017-4292-1","volume":"295","author":"A Salomon-Perzy\u0144ski","year":"2017","unstructured":"Salomon-Perzy\u0144ski A, Salomon-Perzy\u0144ska M, Michalski B, Skrzypulec-Plinta V. High-grade serous ovarian cancer: the clone wars. Arch Gynecol Obstet. 2017;295(3):569\u201376. https:\/\/doi.org\/10.1007\/s00404-017-4292-1.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"2080_CR7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms20040952","volume":"20","author":"M-A Lisio","year":"2019","unstructured":"Lisio M-A, Fu L, Goyeneche A, Gao Z, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952. https:\/\/doi.org\/10.3390\/ijms20040952.","journal-title":"Int J Mol Sci"},{"key":"2080_CR8","doi-asserted-by":"publisher","first-page":"104603","DOI":"10.1016\/j.critrevonc.2024.104603","volume":"208","author":"A Santoro","year":"2025","unstructured":"Santoro A, Angelico G, Travaglino A, Inzani F, Spadola S, Pettinato A, et al. The multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features. Crit Rev Oncol\/Hematol. 2025;208:104603. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104603.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"7353","key":"2080_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315. https:\/\/doi.org\/10.1038\/nature10166.","journal-title":"Nature"},{"issue":"1","key":"2080_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11033-025-11394-2","volume":"53","author":"M Ghanbari","year":"2025","unstructured":"Ghanbari M, Aghazadeh A, Alhajamee M, Jebur MII, Alamara DO, Ghalib MM, et al. Distinct origins of high-grade serous ovarian carcinoma: genetic and epigenetic evidence linking ovarian and fallopian tube epithelium to clinical outcomes and early detection. Mol Biol Rep. 2025;53(1):227. https:\/\/doi.org\/10.1007\/s11033-025-11394-2.","journal-title":"Mol Biol Rep"},{"issue":"3","key":"2080_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3390\/cancers13030468","volume":"13","author":"C-F Hsu","year":"2021","unstructured":"Hsu C-F, Chen P-C, Seenan V, Ding D-C, Chu T-Y. Ovulatory follicular fluid facilitates the full transformation process for the development of High-Grade serous carcinoma. Cancers. 2021;13(3):468. https:\/\/doi.org\/10.3390\/cancers13030468.","journal-title":"Cancers"},{"key":"2080_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.semcancer.2017.08.003","volume":"51","author":"Y Natanzon","year":"2018","unstructured":"Natanzon Y, Goode EL, Cunningham JM. Epigenetics in ovarian cancer. Semin Cancer Biol. 2018;51:160\u20139. https:\/\/doi.org\/10.1016\/j.semcancer.2017.08.003.","journal-title":"Semin Cancer Biol"},{"key":"2080_CR13","doi-asserted-by":"publisher","unstructured":"Tan SYX, Zhang J, Tee W-W. Epigenetic regulation of inflammatory signaling and Inflammation-Induced cancer. Front Cell Dev Biol. 2022;10. https:\/\/doi.org\/10.3389\/fcell.2022.931493.","DOI":"10.3389\/fcell.2022.931493"},{"issue":"1","key":"2080_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s42003-024-06909-9","volume":"7","author":"W Croft","year":"2024","unstructured":"Croft W, Pounds R, Jeevan D, Singh K, Balega J, Sundar S, et al. The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells. Commun Biol. 2024;7(1):1211. https:\/\/doi.org\/10.1038\/s42003-024-06909-9.","journal-title":"Commun Biol"},{"issue":"1","key":"2080_CR15","doi-asserted-by":"publisher","first-page":"e174013","DOI":"10.1172\/JCI174013","volume":"134","author":"Y Wang","year":"2024","unstructured":"Wang Y, Duval AJ, Adli M, Matei D. Biology-driven therapy advances in high-grade serous ovarian cancer. J Clin Invest. 2024;134(1):e174013. https:\/\/doi.org\/10.1172\/JCI174013.","journal-title":"J Clin Invest"},{"key":"2080_CR16","volume-title":"Inflammation and the microcirculation [Internet]","author":"DN Granger","year":"2010","unstructured":"Granger DN, Senchenkova E. Inflammation and the microcirculation [Internet]. San Rafael: Morgan & Claypool Life Sciences; 2010."},{"key":"2080_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/JIR.S503479","volume":"18","author":"C Liu","year":"2025","unstructured":"Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B, et al. Inflammation and immune escape in ovarian cancer: pathways and therapeutic opportunities. JIR. 2025;18:895\u2013909. https:\/\/doi.org\/10.2147\/JIR.S503479.","journal-title":"JIR"},{"issue":"18","key":"2080_CR18","doi-asserted-by":"publisher","first-page":"10719","DOI":"10.3390\/ijms231810719","volume":"23","author":"S Alfaro","year":"2022","unstructured":"Alfaro S, Acu\u00f1a V, Ceriani R, Cavieres MF, Weinstein-Oppenheimer CR, Campos-Estrada C. Involvement of inflammation and its resolution in disease and therapeutics. Int J Mol Sci. 2022;23(18):10719. https:\/\/doi.org\/10.3390\/ijms231810719.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2080_CR19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/cancers10080266","volume":"10","author":"NG Nwani","year":"2018","unstructured":"Nwani NG, Sima LE, Nieves-Neira W, Matei D. Targeting the microenvironment in high grade serous ovarian cancer. Cancers (Basel). 2018;10(8):266. https:\/\/doi.org\/10.3390\/cancers10080266.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2080_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cyto.2012.01.015","volume":"58","author":"A Macci\u00f2","year":"2012","unstructured":"Macci\u00f2 A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012;58(2):133\u201347. https:\/\/doi.org\/10.1016\/j.cyto.2012.01.015.","journal-title":"Cytokine"},{"issue":"8","key":"2080_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/cancers10080251","volume":"10","author":"SS Savant","year":"2018","unstructured":"Savant SS, Sriramkumar S, O\u2019Hagan HM. The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer. Cancers (Basel). 2018;10(8):251. https:\/\/doi.org\/10.3390\/cancers10080251.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2080_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cancers11010021","volume":"11","author":"MS Stack","year":"2018","unstructured":"Stack MS, Nephew KP, Burdette JE, Mitra K. The tumor microenvironment of high grade serous ovarian cancer. Cancers. 2018;11(1):21. https:\/\/doi.org\/10.3390\/cancers11010021.","journal-title":"Cancers"},{"issue":"16","key":"2080_CR23","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198\u2013208. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0196.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2080_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/biolre\/ioz099","volume":"101","author":"DP Cook","year":"2019","unstructured":"Cook DP, Vanderhyden BC. Ovarian cancer and the evolution of subtype classifications using transcriptional profiling. Biol Reprod. 2019;101(3):645\u201358. https:\/\/doi.org\/10.1093\/biolre\/ioz099.","journal-title":"Biol Reprod"},{"issue":"11","key":"2080_CR25","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41416-021-01692-4","volume":"126","author":"J Sun","year":"2022","unstructured":"Sun J, Yan C, Xu D, Zhang Z, Li K, Li X, et al. Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy. Br J Cancer. 2022;126(11):1570\u201380. https:\/\/doi.org\/10.1038\/s41416-021-01692-4.","journal-title":"Br J Cancer"},{"key":"2080_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/JIR.S503479","volume":"18","author":"C Liu","year":"2025","unstructured":"Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B, et al. Inflammation and immune escape in ovarian cancer: pathways and therapeutic opportunities. J Inflamm Res. 2025;18:895\u2013909. https:\/\/doi.org\/10.2147\/JIR.S503479.","journal-title":"J Inflamm Res"},{"key":"2080_CR27","unstructured":"Cameron MJ, Kelvin DJ, Cytokines. Chemokines and their receptors. Madame Curie Bioscience Database [Internet]. Landes Bioscience; 2013."},{"key":"2080_CR28","doi-asserted-by":"publisher","unstructured":"Khalaf K, Hana D, Chou JT-T, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.656364.","DOI":"10.3389\/fimmu.2021.656364"},{"issue":"4","key":"2080_CR29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming growth Factor-\u03b2 signaling in immunity and cancer. Immunity. 2019;50(4):924\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.024.","journal-title":"Immunity"},{"issue":"8","key":"2080_CR30","doi-asserted-by":"publisher","first-page":"a022053","DOI":"10.1101\/cshperspect.a022053","volume":"8","author":"C-H Heldin","year":"2016","unstructured":"Heldin C-H, Moustakas A. Signaling receptors for TGF-\u03b2 family members. Cold Spring Harb Perspect Biol. 2016;8(8):a022053. https:\/\/doi.org\/10.1101\/cshperspect.a022053.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"18","key":"2080_CR31","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1158\/1078-0432.CCR-16-3272","volume":"23","author":"Q Hu","year":"2017","unstructured":"Hu Q, Hisamatsu T, Haemmerle M, Cho MS, Pradeep S, Rupaimoole R, et al. Role of platelet-derived Tgf\u03b21 in the progression of ovarian cancer. Clin Cancer Res. 2017;23(18):5611\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3272.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2080_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3892\/mmr.2017.7970","volume":"17","author":"S Liu","year":"2018","unstructured":"Liu S, Chen S, Zeng J. TGF\u2013\u03b2 signaling: a complex role in tumorigenesis (review). Mol Med Rep. 2018;17(1):699\u2013704. https:\/\/doi.org\/10.3892\/mmr.2017.7970.","journal-title":"Mol Med Rep"},{"issue":"5","key":"2080_CR33","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/cancers11050668","volume":"11","author":"BM Roane","year":"2019","unstructured":"Roane BM, Arend RC, Birrer MJ, Review. Targeting the transforming growth factor-beta pathway in ovarian cancer. Cancers. 2019;11(5):668. https:\/\/doi.org\/10.3390\/cancers11050668.","journal-title":"Cancers"},{"issue":"22","key":"2080_CR34","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-21-0536","volume":"81","author":"LSM Lecker","year":"2021","unstructured":"Lecker LSM, Berlato C, Maniati E, Delaine-Smith R, Pearce OMT, Heath O, et al. TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer. Cancer Res. 2021;81(22):5706\u201319. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0536.","journal-title":"Cancer Res"},{"issue":"1","key":"2080_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12935-023-03061-y","volume":"23","author":"Q Wu","year":"2023","unstructured":"Wu Q, He X, Liu J, Ou C, Li Y, Fu X. Integrative evaluation and experimental validation of the immune-modulating potential of dysregulated extracellular matrix genes in high-grade serous ovarian cancer prognosis. Cancer Cell Int. 2023;23(1):223. https:\/\/doi.org\/10.1186\/s12935-023-03061-y.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"2080_CR36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ygyno.2018.11.014","volume":"152","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Wang C, Cliby WA. Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer. Gynecol Oncol. 2019;152(2):368\u201374. https:\/\/doi.org\/10.1016\/j.ygyno.2018.11.014.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"2080_CR37","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3390\/genes12071103","volume":"12","author":"M-H Sohn","year":"2021","unstructured":"Sohn M-H, Kim SI, Shin J-Y, Kim HS, Chung HH, Kim J-W, et al. Classification of high-grade serous ovarian carcinoma by epithelial-to-mesenchymal transition signature and homologous recombination repair genes. Genes. 2021;12(7):1103. https:\/\/doi.org\/10.3390\/genes12071103.","journal-title":"Genes"},{"issue":"2","key":"2080_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/cancers14020404","volume":"14","author":"Y Belotti","year":"2022","unstructured":"Belotti Y, Lim EH, Lim CT. The role of the extracellular matrix and Tumor-Infiltrating immune cells in the prognostication of High-Grade serous ovarian cancer. Cancers. 2022;14(2):404. https:\/\/doi.org\/10.3390\/cancers14020404.","journal-title":"Cancers"},{"issue":"7","key":"2080_CR39","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1158\/1078-0432.CCR-21-2984","volume":"28","author":"RC Arend","year":"2022","unstructured":"Arend RC, Scalise CB, Gordon ER, Davis AM, Foxall ME, Johnston BE, et al. Metabolic alterations and WNT signaling impact immune response in HGSOC. Clin Cancer Res. 2022;28(7):1433\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2984.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2080_CR40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41419-025-07646-5","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Yu X, Wen L, Wang J, Li Z, Zhang Y, et al. USP9X integrates TGF-\u03b2 and hypoxia signalings to promote ovarian cancer chemoresistance via HIF-2\u03b1-maintained stemness. Cell Death Dis. 2025;16(1):312. https:\/\/doi.org\/10.1038\/s41419-025-07646-5.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2080_CR41","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50(4):907\u201323. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.025.","journal-title":"Immunity"},{"issue":"1","key":"2080_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res. 2020;8(1):49. https:\/\/doi.org\/10.1186\/s40364-020-00228-x.","journal-title":"Biomark Res"},{"key":"2080_CR43","doi-asserted-by":"publisher","first-page":"1087620","DOI":"10.3389\/fimmu.2022.1087620","volume":"13","author":"T Liu","year":"2022","unstructured":"Liu T, Li Y, Wang X, Yang X, Fu Y, Zheng Y, et al. The role of interferons in ovarian cancer progression: hinderer or promoter? Front Immunol. 2022;13:1087620. https:\/\/doi.org\/10.3389\/fimmu.2022.1087620.","journal-title":"Front Immunol"},{"key":"2080_CR44","doi-asserted-by":"publisher","unstructured":"von Locquenghien M, Rozal\u00e9n C, Celi\u00e0-Terrassa T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest 131(1):e143296. https:\/\/doi.org\/10.1172\/JCI143296","DOI":"10.1172\/JCI143296"},{"issue":"1","key":"2080_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41698-019-0103-4","volume":"3","author":"H Cardenas","year":"2019","unstructured":"Cardenas H, Jiang G, Thomes Pepin J, Parker JB, Condello S, Nephew KP, et al. Interferon-\u03b3 signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer. NPJ Precis Oncol. 2019;3(1):32. https:\/\/doi.org\/10.1038\/s41698-019-0103-4.","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"2080_CR46","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/cancers10120464","volume":"10","author":"T-L Yeung","year":"2018","unstructured":"Yeung T-L, Tsai CC, Leung CS, Au Yeung C-L, Thompson MS, Lu KH, et al. ISG15 promotes ERK1 ISGylation, CD8\u2009+\u2009T cell activation and suppresses ovarian cancer progression. Cancers. 2018;10(12):464. https:\/\/doi.org\/10.3390\/cancers10120464.","journal-title":"Cancers"},{"key":"2080_CR47","doi-asserted-by":"publisher","first-page":"886170","DOI":"10.3389\/fgene.2022.886170","volume":"13","author":"NT Bound","year":"2022","unstructured":"Bound NT, Vandenberg CJ, Kartikasari AER, Plebanski M, Scott CL. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: a focus on the immune system. Front Genet. 2022;13:886170. https:\/\/doi.org\/10.3389\/fgene.2022.886170.","journal-title":"Front Genet"},{"issue":"8","key":"2080_CR48","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/cancers15082361","volume":"15","author":"G Raspaglio","year":"2023","unstructured":"Raspaglio G, Buttarelli M, Cappoli N, Ciucci A, Fagotti A, Scambia G, et al. Exploring the control of PARP1 levels in high-grade serous ovarian cancer. Cancers. 2023;15(8):2361. https:\/\/doi.org\/10.3390\/cancers15082361.","journal-title":"Cancers"},{"issue":"3","key":"2080_CR49","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ygyno.2014.06.025","volume":"134","author":"S Cohen","year":"2014","unstructured":"Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, et al. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Gynecol Oncol. 2014;134(3):591\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.025.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2080_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-019-00489-1","volume":"43","author":"D Cruceriu","year":"2020","unstructured":"Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr). 2020;43(1):1\u201318. https:\/\/doi.org\/10.1007\/s13402-019-00489-1.","journal-title":"Cell Oncol (Dordr)"},{"issue":"5","key":"2080_CR51","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"D-I Jang","year":"2021","unstructured":"Jang D-I, Lee A-H, Shin H-Y, Song H-R, Park J-H, Kang T-B, et al. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719. https:\/\/doi.org\/10.3390\/ijms22052719.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2080_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-019-2780-5","volume":"20","author":"E Jo","year":"2020","unstructured":"Jo E, Jang H-J, Yang KE, Jang MS, Huh YH, Yoo H-S, et al. Cordyceps militaris induces apoptosis in ovarian cancer cells through TNF-\u03b1\/TNFR1-mediated Inhibition of NF-\u03baB phosphorylation. BMC Complement Med Ther. 2020;20(1):1. https:\/\/doi.org\/10.1186\/s12906-019-2780-5.","journal-title":"BMC Complement Med Ther"},{"key":"2080_CR53","doi-asserted-by":"publisher","first-page":"155214","DOI":"10.1016\/j.cyto.2020.155214","volume":"135","author":"SK Schr\u00f6der","year":"2020","unstructured":"Schr\u00f6der SK, Asimakopoulou A, Tillmann S, Koschmieder S, Weiskirchen R. TNF-\u03b1 controls Lipocalin-2 expression in PC-3 prostate cancer cells. Cytokine. 2020;135:155214. https:\/\/doi.org\/10.1016\/j.cyto.2020.155214.","journal-title":"Cytokine"},{"issue":"1","key":"2080_CR54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4143\/crt.2019.145","volume":"52","author":"G-P Zhang","year":"2020","unstructured":"Zhang G-P, Yue X, Li S-Q. Cathepsin C interacts with TNF-\u03b1\/p38 MAPK signaling pathway to promote proliferation and metastasis in hepatocellular carcinoma. Cancer Res Treat. 2020;52(1):10\u201323. https:\/\/doi.org\/10.4143\/crt.2019.145.","journal-title":"Cancer Res Treat"},{"key":"2080_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.humpath.2016.03.006","volume":"54","author":"M Gupta","year":"2016","unstructured":"Gupta M, Babic A, Beck AH, Terry K. TNF-\u03b1 expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis? Hum Pathol. 2016;54:82\u201391. https:\/\/doi.org\/10.1016\/j.humpath.2016.03.006.","journal-title":"Hum Pathol"},{"issue":"8","key":"2080_CR56","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1002\/1097-0142(19931015)72","volume":"72","author":"MM Moradi","year":"1993","unstructured":"Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer. 1993;72(8):2433\u201340. https:\/\/doi.org\/10.1002\/1097-0142(19931015)72. :8%253C2433::aid-cncr2820720822%253E3.0.co;2-l.","journal-title":"Cancer"},{"issue":"2","key":"2080_CR57","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1158\/1535-7163.MCT-05-0303","volume":"5","author":"PW Szlosarek","year":"2006","unstructured":"Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, et al. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther. 2006;5(2):382\u201390. https:\/\/doi.org\/10.1158\/1535-7163.MCT-05-0303.","journal-title":"Mol Cancer Ther"},{"key":"2080_CR58","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-2941","author":"H Kulbe","year":"2007","unstructured":"Kulbe H, Kulbe H, Thompson RG, Thompson RG, Wilson JL, Wilson JL, et al. The inflammatory cytokine tumor necrosis factor-\u03b1 generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007. https:\/\/doi.org\/10.1158\/0008-5472.can-06-2941.","journal-title":"Cancer Res"},{"issue":"10","key":"2080_CR59","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1172\/JCI39065","volume":"119","author":"KA Charles","year":"2009","unstructured":"Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009;119(10):3011\u201323. https:\/\/doi.org\/10.1172\/JCI39065.","journal-title":"J Clin Invest"},{"issue":"7","key":"2080_CR60","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/cas.14455","volume":"111","author":"Y Yoshimatsu","year":"2020","unstructured":"Yoshimatsu Y, Wakabayashi I, Kimuro S, Takahashi N, Takahashi K, Kobayashi M, et al. TNF-\u03b1 enhances TGF-\u03b2-induced endothelial-to-mesenchymal transition via TGF-\u03b2 signal augmentation. Cancer Sci. 2020;111(7):2385\u201399. https:\/\/doi.org\/10.1111\/cas.14455.","journal-title":"Cancer Sci"},{"issue":"3","key":"2080_CR61","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/cancers15030667","volume":"15","author":"NC Kampan","year":"2023","unstructured":"Kampan NC, Kartikasari AER, Deceneux C, Madondo MT, McNally OM, Flanagan KL, et al. Combining TNFR2-expressing tregs and IL-6 as superior diagnostic biomarkers for high-grade serous ovarian cancer masses. Cancers. 2023;15(3):667. https:\/\/doi.org\/10.3390\/cancers15030667.","journal-title":"Cancers"},{"issue":"2","key":"2080_CR62","doi-asserted-by":"publisher","first-page":"e06099","DOI":"10.1016\/j.heliyon.2021.e06099","volume":"7","author":"V Kocbek","year":"2021","unstructured":"Kocbek V, Imboden S, Nirgianakis K, Mueller M, McKinnon B. Dual influence of TNF\u03b1 on diverse in vitro models of ovarian cancer subtypes. Heliyon. 2021;7(2):e06099. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e06099.","journal-title":"Heliyon"},{"issue":"10","key":"2080_CR63","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. https:\/\/doi.org\/10.1101\/cshperspect.a016295.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2080_CR64","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/s41598-020-59009-z","volume":"10","author":"NC Kampan","year":"2020","unstructured":"Kampan NC, Madondo MT, Reynolds J, Hallo J, McNally OM, Jobling TW, et al. Pre-operative Sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer. Sci Rep. 2020;10:2213. https:\/\/doi.org\/10.1038\/s41598-020-59009-z.","journal-title":"Sci Rep"},{"issue":"2","key":"2080_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125\u201339. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.09.004.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2080_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12964-017-0172-3","volume":"15","author":"P Ortiz-Montero","year":"2017","unstructured":"Ortiz-Montero P, Londo\u00f1o-Vallejo A, Vernot J-P, Senescence-associated. IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence\/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. Cell Commun Signal. 2017;15(1):17. https:\/\/doi.org\/10.1186\/s12964-017-0172-3.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"2080_CR67","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.18632\/oncotarget.13577","volume":"8","author":"M Sapochnik","year":"2016","unstructured":"Sapochnik M, Haedo MR, Fuertes M, Ajler P, Carrizo G, Cervio A, et al. Autocrine IL-6 mediates pituitary tumor senescence. Oncotarget. 2016;8(3):4690\u2013702. https:\/\/doi.org\/10.18632\/oncotarget.13577.","journal-title":"Oncotarget"},{"issue":"11","key":"2080_CR68","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41416-018-0078-x","volume":"118","author":"R Bharti","year":"2018","unstructured":"Bharti R, Dey G, Das AK, Mandal M. Differential expression of IL-6\/IL-6R and MAO-A regulates invasion\/angiogenesis in breast cancer. Br J Cancer. 2018;118(11):1442\u201352. https:\/\/doi.org\/10.1038\/s41416-018-0078-x.","journal-title":"Br J Cancer"},{"key":"2080_CR69","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.biopha.2018.09.067","volume":"108","author":"S Gao","year":"2018","unstructured":"Gao S, Hu J, Wu X, Liang Z. PMA treated THP-1-derived-IL-6 promotes EMT of SW48 through STAT3\/ERK-dependent activation of Wnt\/\u03b2-catenin signaling pathway. Biomed Pharmacother. 2018;108:618\u201324. https:\/\/doi.org\/10.1016\/j.biopha.2018.09.067.","journal-title":"Biomed Pharmacother"},{"key":"2080_CR70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cytogfr.2018.04.002","volume":"41","author":"K Ray","year":"2018","unstructured":"Ray K, Ujvari B, Ramana V, Donald J. Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. Cytokine Growth Factor Rev. 2018;41:18\u201327. https:\/\/doi.org\/10.1016\/j.cytogfr.2018.04.002.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2080_CR71","doi-asserted-by":"publisher","unstructured":"Manore SG, Doheny DL, Wong GL, Lo H-W. IL-6\/JAK\/STAT3 signaling in breast cancer metastasis: biology and treatment. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.866014.","DOI":"10.3389\/fonc.2022.866014"},{"key":"2080_CR72","doi-asserted-by":"publisher","unstructured":"Xu J, Lin H, Wu G, Zhu M, Li M. IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.760971.","DOI":"10.3389\/fonc.2021.760971"},{"issue":"1","key":"2080_CR73","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41467-021-21976-w","volume":"12","author":"B Zhang","year":"2021","unstructured":"Zhang B, Li Y, Wu Q, Xie L, Barwick B, Fu C, et al. Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nat Commun. 2021;12(1):1714. https:\/\/doi.org\/10.1038\/s41467-021-21976-w.","journal-title":"Nat Commun"},{"issue":"4","key":"2080_CR74","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/0002-9378(91)90582-c","volume":"164","author":"JS Berek","year":"1991","unstructured":"Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Mart\u00ednez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164(4):1038\u201342. https:\/\/doi.org\/10.1016\/0002-9378(91)90582-c. discussion 1042\u20131043.","journal-title":"Am J Obstet Gynecol"},{"key":"2080_CR75","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/1471-2407-11-210","volume":"11","author":"D Lane","year":"2011","unstructured":"Lane D, Matte I, Rancourt C, Pich\u00e9 A. Prognostic significance of IL-6 and IL-8 Ascites levels in ovarian cancer patients. BMC Cancer. 2011;11:210. https:\/\/doi.org\/10.1186\/1471-2407-11-210.","journal-title":"BMC Cancer"},{"key":"2080_CR76","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13048-015-0183-x","volume":"8","author":"S Masoumi-Moghaddam","year":"2015","unstructured":"Masoumi-Moghaddam S, Amini A, Wei A-Q, Robertson G, Morris DL. Intratumoral interleukin-6 predicts Ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring. J Ovarian Res. 2015;8:58. https:\/\/doi.org\/10.1186\/s13048-015-0183-x.","journal-title":"J Ovarian Res"},{"issue":"2","key":"2080_CR77","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/bjc.1995.71","volume":"71","author":"G Scambia","year":"1995","unstructured":"Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, et al. Prognostic significance of Interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71(2):354\u20136.","journal-title":"Br J Cancer"},{"issue":"2","key":"2080_CR78","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cyto.2012.04.020","volume":"59","author":"Y Wang","year":"2012","unstructured":"Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, et al. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine. 2012;59(2):228\u201336. https:\/\/doi.org\/10.1016\/j.cyto.2012.04.020.","journal-title":"Cytokine"},{"issue":"10","key":"2080_CR79","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1111\/j.1349-7006.2010.01652.x","volume":"101","author":"K Takaishi","year":"2010","unstructured":"Takaishi K, Komohara Y, Tashiro H, Ohtake H, Nakagawa T, Katabuchi H, et al. Involvement of M2-polarized macrophages in the Ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 2010;101(10):2128\u201336. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01652.x.","journal-title":"Cancer Sci"},{"key":"2080_CR80","unstructured":"Rabinovich A, Rabinovich A, Medina L, Medina L, Piura B, Piura B, et al. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res. 2007."},{"issue":"3","key":"2080_CR81","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1006\/gyno.1998.4974","volume":"69","author":"A Macci\u00f2","year":"1998","unstructured":"Macci\u00f2 A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69(3):248\u201352. https:\/\/doi.org\/10.1006\/gyno.1998.4974.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"2080_CR82","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1073\/pnas.87.8.3092","volume":"87","author":"B Motro","year":"1990","unstructured":"Motro B, Itin A, Sachs L, Keshet E. Pattern of Interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A. 1990;87(8):3092\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2080_CR83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1189\/jlb.1105674","volume":"80","author":"S Rose-John","year":"2006","unstructured":"Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80(2):227\u201336. https:\/\/doi.org\/10.1189\/jlb.1105674.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"2080_CR84","first-page":"566","volume":"2","author":"I Matte","year":"2012","unstructured":"Matte I, Lane D, Laplante C, Rancourt C, Pich\u00e9 A. Profiling of cytokines in human epithelial ovarian cancer Ascites. Am J Cancer Res. 2012;2(5):566\u201380.","journal-title":"Am J Cancer Res"},{"issue":"23","key":"2080_CR85","doi-asserted-by":"publisher","first-page":"e122360","DOI":"10.1172\/jci.insight.122360","volume":"3","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zong X, Mitra S, Mitra AK, Matei D, Nephew KP. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. JCI Insight. 2018;3(23):e122360. https:\/\/doi.org\/10.1172\/jci.insight.122360.","journal-title":"JCI Insight"},{"issue":"10","key":"2080_CR86","doi-asserted-by":"publisher","first-page":"e002873","DOI":"10.1136\/jitc-2021-002873","volume":"9","author":"J Fucikova","year":"2021","unstructured":"Fucikova J, Coosemans A, Orsulic S, Cibula D, Vergote I, Galluzzi L, et al. Immunological configuration of ovarian carcinoma: features and impact on disease outcome. J Immunother Cancer. 2021;9(10):e002873. https:\/\/doi.org\/10.1136\/jitc-2021-002873.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2080_CR87","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.celrep.2019.12.034","volume":"30","author":"E Maniati","year":"2020","unstructured":"Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, et al. Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment. Cell Rep. 2020;30(2):525\u2013e5407. https:\/\/doi.org\/10.1016\/j.celrep.2019.12.034.","journal-title":"Cell Rep"},{"issue":"4","key":"2080_CR88","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/molehr\/2.4.245","volume":"2","author":"E Runesson","year":"1996","unstructured":"Runesson E, Bostr\u00f6m EK, Janson PO, Br\u00e4nnstr\u00f6m M. The human preovulatory follicle is a source of the chemotactic cytokine interleukin-8. Mol Hum Reprod. 1996;2(4):245\u201350. https:\/\/doi.org\/10.1093\/molehr\/2.4.245.","journal-title":"Mol Hum Reprod"},{"issue":"3","key":"2080_CR89","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1006\/gyno.1998.5198","volume":"71","author":"K Ivarsson","year":"1998","unstructured":"Ivarsson K, Runesson E, Sundfeldt K, Haeger M, Hedin L, Janson PO, et al. The chemotactic cytokine interleukin-8\u2013a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol. 1998;71(3):420\u20133. https:\/\/doi.org\/10.1006\/gyno.1998.5198.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2080_CR90","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.clinbiochem.2004.01.014","volume":"37","author":"SK Kassim","year":"2004","unstructured":"Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam EE, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004;37(5):363\u20139. https:\/\/doi.org\/10.1016\/j.clinbiochem.2004.01.014.","journal-title":"Clin Biochem"},{"issue":"2","key":"2080_CR91","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-2007-1022247","volume":"56","author":"J Radke","year":"1996","unstructured":"Radke J, Schmidt D, B\u00f6hme M, Schmidt U, Weise W, Morenz J. [-Cytokine level in malignant Ascites and peripheral blood of patients with advanced ovarian carcinoma-]. Geburtshilfe Frauenheilkd. 1996;56(2):83\u20137. https:\/\/doi.org\/10.1055\/s-2007-1022247.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"1","key":"2080_CR92","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cyto.2012.04.013","volume":"59","author":"Y Wang","year":"2012","unstructured":"Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012;59(1):145\u201355. https:\/\/doi.org\/10.1016\/j.cyto.2012.04.013.","journal-title":"Cytokine"},{"issue":"3","key":"2080_CR93","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/bjc.1995.398","volume":"72","author":"K Hirose","year":"1995","unstructured":"Hirose K, Hakozaki M, Nyunoya Y, Kobayashi Y, Matsushita K, Takenouchi T, et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer. 1995;72(3):708\u201314.","journal-title":"Br J Cancer"},{"issue":"5","key":"2080_CR94","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.4049\/jimmunol.164.5.2769","volume":"164","author":"LF Lee","year":"2000","unstructured":"Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol. 2000;164(5):2769\u201375. https:\/\/doi.org\/10.4049\/jimmunol.164.5.2769.","journal-title":"J Immunol"},{"issue":"2","key":"2080_CR95","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF00916100","volume":"17","author":"DE Hu","year":"1993","unstructured":"Hu DE, Hori Y, Fan TP. Interleukin-8 stimulates angiogenesis in rats. Inflammation. 1993;17(2):135\u201343. https:\/\/doi.org\/10.1007\/BF00916100.","journal-title":"Inflammation"},{"issue":"9","key":"2080_CR96","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1172\/JCI6870","volume":"103","author":"WG Stetler-Stevenson","year":"1999","unstructured":"Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999;103(9):1237\u201341. https:\/\/doi.org\/10.1172\/JCI6870.","journal-title":"J Clin Invest"},{"issue":"2","key":"2080_CR97","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3390\/cancers12020505","volume":"12","author":"B Muqaku","year":"2020","unstructured":"Muqaku B, Pils D, Mader JC, Aust S, Mangold A, Muqaku L, et al. Neutrophil extracellular trap formation correlates with favorable overall survival in high grade ovarian cancer. Cancers. 2020;12(2):505. https:\/\/doi.org\/10.3390\/cancers12020505.","journal-title":"Cancers"},{"issue":"12","key":"2080_CR98","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.3390\/vaccines10122121","volume":"10","author":"P Kumar","year":"2022","unstructured":"Kumar P, Ranmale S, Tongaonkar H, Mania-Pramanik J. Immune profile of blood, tissue and peritoneal fluid: a comparative study in high grade serous epithelial ovarian cancer patients at interval debulking surgery. Vaccines. 2022;10(12):2121. https:\/\/doi.org\/10.3390\/vaccines10122121.","journal-title":"Vaccines"},{"issue":"6","key":"2080_CR99","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.3390\/ijms24065995","volume":"24","author":"M Casta\u00f1o","year":"2023","unstructured":"Casta\u00f1o M, Tom\u00e1s-P\u00e9rez S, Gonz\u00e1lez-Cant\u00f3 E, Aghababyan C, Mascar\u00f3s-Mart\u00ednez A, Santonja N, et al. Neutrophil extracellular traps and cancer: trapping our attention with their involvement in ovarian cancer. Int J Mol Sci. 2023;24(6):5995. https:\/\/doi.org\/10.3390\/ijms24065995.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2080_CR100","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3390\/ijms19082155","volume":"19","author":"R Bent","year":"2018","unstructured":"Bent R, Moll L, Grabbe S, Bros M. Interleukin-1 beta-a friend or foe in malignancies? Int J Mol Sci. 2018;19(8):2155. https:\/\/doi.org\/10.3390\/ijms19082155.","journal-title":"Int J Mol Sci"},{"key":"2080_CR101","doi-asserted-by":"publisher","unstructured":"Fahey E, Doyle SL. IL-1 family cytokine regulation of vascular permeability and angiogenesis. Front Immunol. 2019;10. https:\/\/doi.org\/10.3389\/fimmu.2019.01426.","DOI":"10.3389\/fimmu.2019.01426"},{"issue":"1","key":"2080_CR102","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/imr.12615","volume":"281","author":"A Malik","year":"2018","unstructured":"Malik A, Kanneganti T-D. Function and regulation of IL-1\u03b1 in inflammatory diseases and cancer. Immunol Rev. 2018;281(1):124\u201337. https:\/\/doi.org\/10.1111\/imr.12615.","journal-title":"Immunol Rev"},{"key":"2080_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-38315-2_1","volume-title":"Tumor microenvironment: the role of interleukins\u2014part A","author":"W Zhang","year":"2020","unstructured":"Zhang W, Borcherding N, Kolb R. IL-1 signaling in tumor microenvironment. In: Birbrair A, editor. Tumor microenvironment: the role of interleukins\u2014part A. Cham: Springer; 2020. pp. 1\u201323. https:\/\/doi.org\/10.1007\/978-3-030-38315-2_1."},{"issue":"3","key":"2080_CR104","doi-asserted-by":"publisher","first-page":"109412","DOI":"10.1016\/j.celrep.2021.109412","volume":"36","author":"M Bruand","year":"2021","unstructured":"Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, et al. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Rep. 2021;36(3):109412. https:\/\/doi.org\/10.1016\/j.celrep.2021.109412.","journal-title":"Cell Rep"},{"issue":"3","key":"2080_CR105","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.4110\/in.2019.19.e22","volume":"19","author":"RMC Ignacio","year":"2019","unstructured":"Ignacio RMC, Lee E-S, Son D-S. Potential roles of innate immune chemokine and cytokine network on lipopolysaccharide-based therapeutic approach in ovarian cancer. Immune Netw. 2019;19(3):e22. https:\/\/doi.org\/10.4110\/in.2019.19.e22.","journal-title":"Immune Netw"},{"issue":"22","key":"2080_CR106","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.7150\/thno.37549","volume":"9","author":"F Finkernagel","year":"2019","unstructured":"Finkernagel F, Reinartz S, Schuldner M, Malz A, Jansen JM, Wagner U, et al. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment. Theranostics. 2019;9(22):6601\u201317. https:\/\/doi.org\/10.7150\/thno.37549.","journal-title":"Theranostics"},{"issue":"2","key":"2080_CR107","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ygyno.2020.08.032","volume":"159","author":"A Madariaga","year":"2020","unstructured":"Madariaga A, Garg S, Bruce JP, Thiryayi S, Mandilaras V, Rath P, et al. Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. Gynecol Oncol. 2020;159(2):539\u201345. https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.032.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2080_CR108","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1095\/biolreprod22.1.73","volume":"22","author":"LL Espey","year":"1980","unstructured":"Espey LL. Ovulation as an inflammatory reaction\u2014a hypothesis. Biol Reprod. 1980;22(1):73\u2013106. https:\/\/doi.org\/10.1095\/biolreprod22.1.73.","journal-title":"Biol Reprod"},{"issue":"3","key":"2080_CR109","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.ajog.2004.10.587","volume":"192","author":"R Ali-Fehmi","year":"2005","unstructured":"Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp V, Malone JM, et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol. 2005;192(3):819\u201325. https:\/\/doi.org\/10.1016\/j.ajog.2004.10.587.","journal-title":"Am J Obstet Gynecol"},{"key":"2080_CR110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1476-4598-5-62","volume":"5","author":"K Rask","year":"2006","unstructured":"Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K. Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer. 2006;5:62. https:\/\/doi.org\/10.1186\/1476-4598-5-62.","journal-title":"Mol Cancer"},{"issue":"5","key":"2080_CR111","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000299085","volume":"18","author":"PK Heinonen","year":"1984","unstructured":"Heinonen PK, Mets\u00e4-Ketel\u00e4 T. Prostaglandin and thromboxane production in ovarian cancer tissue. Gynecol Obstet Invest. 1984;18(5):225\u20139. https:\/\/doi.org\/10.1159\/000299085.","journal-title":"Gynecol Obstet Invest"},{"issue":"24","key":"2080_CR112","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","volume":"71","author":"N Obermajer","year":"2011","unstructured":"Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011;71(24):7463\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2449.","journal-title":"Cancer Res"},{"issue":"5","key":"2080_CR113","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/0008-5472.CAN-05-4063","volume":"66","author":"T Daikoku","year":"2006","unstructured":"Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, et al. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res. 2006;66(5):2527\u201331. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4063.","journal-title":"Cancer Res"},{"issue":"8","key":"2080_CR114","doi-asserted-by":"publisher","first-page":"9741","DOI":"10.3390\/ijms13089741","volume":"13","author":"W Li","year":"2012","unstructured":"Li W, Cai J-H, Zhang J, Tang Y-X, Wan L. Effects of cyclooxygenase inhibitors in combination with taxol on expression of Cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma. Int J Mol Sci. 2012;13(8):9741\u201353. https:\/\/doi.org\/10.3390\/ijms13089741.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2080_CR115","doi-asserted-by":"publisher","first-page":"113246","DOI":"10.1016\/j.celrep.2023.113246","volume":"42","author":"S Chen","year":"2023","unstructured":"Chen S, Wu Y, Gao Y, Wu C, Wang Y, Hou C, et al. Allosterically inhibited PFKL via prostaglandin E2 withholds glucose metabolism and ovarian cancer invasiveness. Cell Rep. 2023;42(10):113246. https:\/\/doi.org\/10.1016\/j.celrep.2023.113246.","journal-title":"Cell Rep"},{"issue":"1","key":"2080_CR116","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-015-0463-5","volume":"14","author":"AJ Wilson","year":"2015","unstructured":"Wilson AJ, Saskowski J, Barham W, Khabele D, Yull F. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer. Mol Cancer. 2015;14(1):192. https:\/\/doi.org\/10.1186\/s12943-015-0463-5.","journal-title":"Mol Cancer"},{"issue":"9","key":"2080_CR117","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.annonc.2020.05.019","volume":"31","author":"J Millstein","year":"2020","unstructured":"Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020;31(9):1240\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.019.","journal-title":"Ann Oncol"},{"key":"2080_CR118","doi-asserted-by":"publisher","first-page":"1381894","DOI":"10.3389\/fonc.2024.1381894","volume":"14","author":"Q Xia","year":"2024","unstructured":"Xia Q, Gao W, Yang J, Xing Z, Ji Z. The deregulation of arachidonic acid metabolism in ovarian cancer. Front Oncol. 2024;14:1381894. https:\/\/doi.org\/10.3389\/fonc.2024.1381894.","journal-title":"Front Oncol"},{"issue":"4","key":"2080_CR119","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.3892\/or.2019.6984","volume":"41","author":"MR Alves","year":"2019","unstructured":"Alves MR, Do Amaral NS, Marchi FA, Silva FIDB, Da Costa AABA, Carvalho KC, et al. Prostaglandin D2 expression is prognostic in high-grade serous ovarian cancer. Oncol Rep. 2019;41(4):2254\u201364. https:\/\/doi.org\/10.3892\/or.2019.6984.","journal-title":"Oncol Rep"},{"issue":"8","key":"2080_CR120","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/cancers11081049","volume":"11","author":"LG Hudson","year":"2019","unstructured":"Hudson LG, Cook LS, Grimes MM, Muller CY, Adams SF, Wandinger-Ness A. Dual actions of ketorolac in metastatic ovarian cancer. Cancers. 2019;11(8):1049. https:\/\/doi.org\/10.3390\/cancers11081049.","journal-title":"Cancers"},{"key":"2080_CR121","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejmech.2019.06.039","volume":"179","author":"A Scilimati","year":"2019","unstructured":"Scilimati A, Ferorelli S, Iaselli MC, Miciaccia M, Pati ML, Fortuna CG, et al. Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection. Eur J Med Chem. 2019;179:16\u201325. https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.039.","journal-title":"Eur J Med Chem"},{"key":"2080_CR122","doi-asserted-by":"publisher","first-page":"946348","DOI":"10.3389\/fphar.2022.946348","volume":"13","author":"S Koller","year":"2022","unstructured":"Koller S, Kendler J, Karacs J, Wolf A, Kreuzinger C, Von Decken D. SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancer. Front Pharmacol. 2022;13:946348. https:\/\/doi.org\/10.3389\/fphar.2022.946348.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2080_CR123","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1210\/jc.2007-1512","volume":"93","author":"S-U Chen","year":"2008","unstructured":"Chen S-U, Chou C-H, Lee H, Ho C-H, Lin C-W, Yang Y-S. Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in granulosa-lutein cells through its receptors and nuclear factor-kappaB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2008;93(3):935\u201343. https:\/\/doi.org\/10.1210\/jc.2007-1512.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2080_CR124","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1095\/biolreprod61.1.195","volume":"61","author":"A Tokumura","year":"1999","unstructured":"Tokumura A, Miyake M, Nishioka Y, Yamano S, Aono T, Fukuzawa K. Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of in vitro fertilization patients. Biol Reprod. 1999;61(1):195\u20139. https:\/\/doi.org\/10.1095\/biolreprod61.1.195.","journal-title":"Biol Reprod"},{"key":"2080_CR125","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1749-6632.2000.tb06550.x","volume":"905","author":"X Fang","year":"2000","unstructured":"Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci. 2000;905:188\u2013208. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06550.x.","journal-title":"Ann N Y Acad Sci"},{"key":"2080_CR126","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-1-4757-3587-1_12","volume":"107","author":"GB Mills","year":"2002","unstructured":"Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, et al. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res. 2002;107:259\u201383. https:\/\/doi.org\/10.1007\/978-1-4757-3587-1_12.","journal-title":"Cancer Treat Res"},{"issue":"4","key":"2080_CR127","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1023\/a:1008217129273","volume":"9","author":"AM Westermann","year":"1998","unstructured":"Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol. 1998;9(4):437\u201342. https:\/\/doi.org\/10.1023\/a:1008217129273.","journal-title":"Ann Oncol"},{"issue":"2","key":"2080_CR128","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1006\/abio.2001.5000","volume":"290","author":"YJ Xiao","year":"2001","unstructured":"Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem. 2001;290(2):302\u201313. https:\/\/doi.org\/10.1006\/abio.2001.5000.","journal-title":"Anal Biochem"},{"key":"2080_CR129","doi-asserted-by":"publisher","unstructured":"Y X ZS, Dw W, Re MW. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280(8). https:\/\/doi.org\/10.1001\/jama.280.8.719.","DOI":"10.1001\/jama.280.8.719"},{"issue":"6","key":"2080_CR130","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1158\/0008.5472.CAN-04-2781","volume":"65","author":"J Symowicz","year":"2005","unstructured":"Symowicz J, Adley BP, Woo MMM, Auersperg N, Hudson LG, Stack MS. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res. 2005;65(6):2234\u201342. https:\/\/doi.org\/10.1158\/0008.5472.CAN-04-2781.","journal-title":"Cancer Res"},{"issue":"10","key":"2080_CR131","first-page":"1223","volume":"1","author":"Y Xu","year":"1995","unstructured":"Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, et al. Characterization of an ovarian cancer activating factor in Ascites from ovarian cancer patients. Clin Cancer Res. 1995;1(10):1223\u201332.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2080_CR132","doi-asserted-by":"publisher","first-page":"9653","DOI":"10.1074\/jbc.M306662200","volume":"279","author":"X Fang","year":"2004","unstructured":"Fang X, Yu S, Bast RC, Liu S, Xu H-J, Hu S-X, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004;279(10):9653\u201361. https:\/\/doi.org\/10.1074\/jbc.M306662200.","journal-title":"J Biol Chem"},{"issue":"12","key":"2080_CR133","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.freeradbiomed.2010.10.663","volume":"49","author":"JA Saunders","year":"2010","unstructured":"Saunders JA, Rogers LC, Klomsiri C, Poole LB, Daniel LW. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med. 2010;49(12):2058\u201367. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2010.10.663.","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"2080_CR134","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1158\/2159-8290.CD-21-1181","volume":"12","author":"C-S Chae","year":"2022","unstructured":"Chae C-S, Sandoval TA, Hwang S-M, Park ES, Giovanelli P, Awasthi D, et al. Tumor-derived lysophosphatidic acid blunts protective type-I interferon responses in ovarian cancer. Cancer Discov. 2022;12(8):1904\u201321. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1181.","journal-title":"Cancer Discov"},{"issue":"1","key":"2080_CR135","doi-asserted-by":"publisher","first-page":"10877","DOI":"10.1038\/s41598-020-67565-7","volume":"10","author":"Y Klymenko","year":"2020","unstructured":"Klymenko Y, Bos B, Campbell L, Loughran E, Liu Y, Yang J, et al. Lysophosphatidic acid modulates ovarian cancer multicellular aggregate assembly and metastatic dissemination. Sci Rep. 2020;10(1):10877. https:\/\/doi.org\/10.1038\/s41598-020-67565-7.","journal-title":"Sci Rep"},{"key":"2080_CR136","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ceca.2019.06.002","volume":"81","author":"S Kouba","year":"2019","unstructured":"Kouba S, Ouldamer L, Garcia C, Fontaine D, Chantome A, Vandier C, et al. Lipid metabolism and calcium signaling in epithelial ovarian cancer. Cell Calcium. 2019;81:38\u201350. https:\/\/doi.org\/10.1016\/j.ceca.2019.06.002.","journal-title":"Cell Calcium"},{"issue":"2","key":"2080_CR137","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1083\/jcb.200206094","volume":"158","author":"WH Moolenaar","year":"2002","unstructured":"Moolenaar WH. Lysophospholipids in the limelight. J Cell Biol. 2002;158(2):197\u20139. https:\/\/doi.org\/10.1083\/jcb.200206094.","journal-title":"J Cell Biol"},{"issue":"2","key":"2080_CR138","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1078-0432.CCR-08-1945","volume":"15","author":"Y Song","year":"2009","unstructured":"Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. Sp-1 and c-Myc mediate lysophosphatidic acid\u2013induced expression of vascular endothelial growth factor in ovarian cancer cells via a Hypoxia-Inducible factor-1\u2013independent mechanism. Clin Cancer Res. 2009;15(2):492\u2013501. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1945.","journal-title":"Clin Cancer Res"},{"key":"2080_CR139","doi-asserted-by":"publisher","unstructured":"Zhao H, Jia P, Nanding K, Wu M, Bai X, Morigen M, et al. Lysophosphatidic acid suppresses apoptosis of high-grade serous ovarian cancer cells by inducing autophagy activity and promotes cell-cycle progression via EGFR-PI3K\/Aurora-AThr288-geminin dual signaling pathways. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.1046269.","DOI":"10.3389\/fphar.2022.1046269"},{"issue":"6917","key":"2080_CR140","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860\u20137. https:\/\/doi.org\/10.1038\/nature01322.","journal-title":"Nature"},{"issue":"4","key":"2080_CR141","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.4110\/in.2018.18.e29","volume":"18","author":"RMC Ignacio","year":"2018","unstructured":"Ignacio RMC, Lee E-S, Wilson AJ, Beeghly-Fadiel A, Whalen MM, Son D-S. Chemokine network and overall survival in TP53 wild-type and mutant ovarian cancer. Immune Netw. 2018;18(4):e29. https:\/\/doi.org\/10.4110\/in.2018.18.e29.","journal-title":"Immune Netw"},{"issue":"8","key":"2080_CR142","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1007\/s43032-023-01188-x","volume":"30","author":"K Zhang","year":"2023","unstructured":"Zhang K, Xie X, Zou L-H, Guo S-Q. Tertiary lymphoid structures are associated with a favorable prognosis in high-grade serous ovarian cancer patients. Reprod Sci. 2023;30(8):2468\u201380. https:\/\/doi.org\/10.1007\/s43032-023-01188-x.","journal-title":"Reprod Sci"},{"issue":"3","key":"2080_CR143","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ijc.28393","volume":"134","author":"A Rainczuk","year":"2014","unstructured":"Rainczuk A, Rao JR, Gathercole JL, Fairweather NJ, Chu S, Masadah R, et al. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours. Intl J Cancer. 2014;134(3):530\u201341. https:\/\/doi.org\/10.1002\/ijc.28393.","journal-title":"Intl J Cancer"},{"issue":"9","key":"2080_CR144","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/cancers10090302","volume":"10","author":"ML Drakes","year":"2018","unstructured":"Drakes ML, Stiff PJ. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers. 2018;10(9):302. https:\/\/doi.org\/10.3390\/cancers10090302.","journal-title":"Cancers"},{"issue":"1","key":"2080_CR145","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/s12935-021-02295-y","volume":"21","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wu Y, Li H, Sun L, Meng X. Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response. Cancer Cell Int. 2021;21(1):593. https:\/\/doi.org\/10.1186\/s12935-021-02295-y.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2080_CR146","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/ijms15010361","volume":"15","author":"GG Muralidhar","year":"2014","unstructured":"Muralidhar GG, Barbolina MV. Chemokine receptors in epithelial ovarian cancer. Int J Mol Sci. 2014;15(1):361\u201376. https:\/\/doi.org\/10.3390\/ijms15010361.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2080_CR147","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.gendis.2014.09.005","volume":"1","author":"CM Teven","year":"2014","unstructured":"Teven CM, Farina EM, Rivas J, Reid RR. Fibroblast growth factor (FGF) signaling in development and skeletal diseases. Genes Dis. 2014;1(2):199\u2013213. https:\/\/doi.org\/10.1016\/j.gendis.2014.09.005.","journal-title":"Genes Dis"},{"issue":"24","key":"2080_CR148","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.7150\/jca.44727","volume":"11","author":"D-L Zhu","year":"2020","unstructured":"Zhu D-L, Tuo X-M, Rong Y, Zhang K, Guo Y. Fibroblast growth factor receptor signaling as therapeutic targets in female reproductive system cancers. J Cancer. 2020;11(24):7264\u201375. https:\/\/doi.org\/10.7150\/jca.44727.","journal-title":"J Cancer"},{"key":"2080_CR149","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.2147\/CMAR.S251622","volume":"12","author":"Y Wu","year":"2020","unstructured":"Wu Y, Xia L, Guo Q, Zhu J, Deng Y, Wu X. Identification of chemoresistance-associated key genes and pathways in high-grade serous ovarian cancer by bioinformatics analyses. Cancer Manag Res. 2020;12:5213\u201323. https:\/\/doi.org\/10.2147\/CMAR.S251622.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"2080_CR150","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","volume":"124","author":"MA Krook","year":"2021","unstructured":"Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021;124(5):880\u201392. https:\/\/doi.org\/10.1038\/s41416-020-01157-0.","journal-title":"Br J Cancer"},{"issue":"3","key":"2080_CR151","doi-asserted-by":"publisher","first-page":"e59083","DOI":"10.1371\/journal.pone.0059083","volume":"8","author":"M-T Lau","year":"2013","unstructured":"Lau M-T, So W-K, Leung PCK. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K\/Akt\/mTOR and MAPK\/ERK signaling in ovarian cancer cells. PLoS ONE. 2013;8(3):e59083. https:\/\/doi.org\/10.1371\/journal.pone.0059083.","journal-title":"PLoS ONE"},{"issue":"5","key":"2080_CR152","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4161\/cbt.10.5.12585","volume":"10","author":"C Cole","year":"2010","unstructured":"Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther. 2010;10(5):495\u2013504. https:\/\/doi.org\/10.4161\/cbt.10.5.12585.","journal-title":"Cancer Biol Ther"},{"key":"2080_CR153","doi-asserted-by":"publisher","first-page":"e14827","DOI":"10.7717\/peerj.14827","volume":"11","author":"W Zhu","year":"2023","unstructured":"Zhu W, Huang M, Thakur A, Yan Y, Wu X. FGF19 promotes cell autophagy and cisplatin chemoresistance by activating MAPK signaling in ovarian cancer. PeerJ. 2023;11:e14827. https:\/\/doi.org\/10.7717\/peerj.14827.","journal-title":"PeerJ"},{"issue":"10","key":"2080_CR154","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1172\/JCI70625","volume":"123","author":"W Wei","year":"2013","unstructured":"Wei W, Mok SC, Oliva E, Kim S, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest. 2013;123(10):4435\u201348. https:\/\/doi.org\/10.1172\/JCI70625.","journal-title":"J Clin Invest"},{"issue":"4","key":"2080_CR155","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1078-0432.CCR-12-2736","volume":"19","author":"TM Zaid","year":"2013","unstructured":"Zaid TM, Yeung T-L, Thompson MS, Leung CS, Harding T, Co N-N, et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage high-grade serous ovarian cancer. Clin Cancer Res. 2013;19(4):809\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2736.","journal-title":"Clin Cancer Res"},{"key":"2080_CR156","doi-asserted-by":"publisher","unstructured":"Adzibolosu N, Alvero AB, Ali-Fehmi R, Gogoi R, Corey L, Tedja R, et al. Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1204148.","DOI":"10.3389\/fimmu.2023.1204148"},{"key":"2080_CR157","doi-asserted-by":"publisher","first-page":"1252700","DOI":"10.3389\/fonc.2023.1252700","volume":"13","author":"E Mairinger","year":"2023","unstructured":"Mairinger E, Wessolly M, Buderath P, Borchert S, Henrich L, Mach P, et al. Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma. Front Oncol. 2023;13:1252700. https:\/\/doi.org\/10.3389\/fonc.2023.1252700.","journal-title":"Front Oncol"},{"issue":"11","key":"2080_CR158","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/mc.22419","volume":"55","author":"Q Wang","year":"2016","unstructured":"Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L, et al. CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 2016;55(11):1688\u201399. https:\/\/doi.org\/10.1002\/mc.22419.","journal-title":"Mol Carcinog"},{"issue":"1","key":"2080_CR159","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13048-024-01586-y","volume":"18","author":"C-Y Chen","year":"2025","unstructured":"Chen C-Y, Wang T-Y, Liu J-L, Ou Y-C, Lee L-W, Hung C-H, et al. Association between cytokines and progression-free survival in ovarian cancer following CRS\/HIPEC treatment. J Ovarian Res. 2025;18(1):3. https:\/\/doi.org\/10.1186\/s13048-024-01586-y.","journal-title":"J Ovarian Res"},{"issue":"6","key":"2080_CR160","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1007\/s13277-015-3133-8","volume":"36","author":"I Wertel","year":"2015","unstructured":"Wertel I, Sur\u00f3wka J, Polak G, Barczy\u0144ski B, Bednarek W, Jakubowicz-Gil J, et al. Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumor Biol. 2015;36(6):4811\u20137. https:\/\/doi.org\/10.1007\/s13277-015-3133-8.","journal-title":"Tumor Biol"},{"key":"2080_CR161","doi-asserted-by":"publisher","first-page":"101130","DOI":"10.1016\/j.neo.2025.101130","volume":"60","author":"S Seitz","year":"2025","unstructured":"Seitz S, Dreyer TF, Stange C, Steiger K, Wohlleber D, Anton M, et al. The chemokine CX3CL1 promotes intraperitoneal tumour growth despite enhanced T-cell recruitment in ovarian cancer. Neoplasia. 2025;60:101130. https:\/\/doi.org\/10.1016\/j.neo.2025.101130.","journal-title":"Neoplasia"},{"issue":"1","key":"2080_CR162","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13048-020-00640-9","volume":"13","author":"M Guo","year":"2020","unstructured":"Guo M, Xu C, Chen Y-Z, Sun Q-W, Zhao X-Y, Liu X, et al. Associations of CXCL1 gene 5\u2019UTR variations with ovarian cancer. J Ovarian Res. 2020;13(1):43. https:\/\/doi.org\/10.1186\/s13048-020-00640-9.","journal-title":"J Ovarian Res"},{"issue":"5","key":"2080_CR163","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/bjc.2016.172","volume":"115","author":"H Bronger","year":"2016","unstructured":"Bronger H, Singer J, Windm\u00fcller C, Reuning U, Zech D, Delbridge C, et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase Inhibition in advanced serous ovarian cancer. Br J Cancer. 2016;115(5):553\u201363. https:\/\/doi.org\/10.1038\/bjc.2016.172.","journal-title":"Br J Cancer"},{"issue":"3","key":"2080_CR164","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ygyno.2017.03.007","volume":"145","author":"K K Au","year":"2017","unstructured":"K Au K, Peterson N, Truesdell P, Reid-Schachter G, Khalaj K, Ren R, et al. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. Gynecol Oncol. 2017;145(3):436\u201345. https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.007.","journal-title":"Gynecol Oncol"},{"issue":"20","key":"2080_CR165","doi-asserted-by":"publisher","first-page":"17943","DOI":"10.1007\/s00432-023-05466-8","volume":"149","author":"P K\u00f6hn","year":"2023","unstructured":"K\u00f6hn P, Lalos A, Posabella A, Wilhelm A, Tampakis A, Caner E, et al. High density of CXCL12-positive immune cell infiltration predicts chemosensitivity and recurrence-free survival in ovarian carcinoma. J Cancer Res Clin Oncol. 2023;149(20):17943\u201355. https:\/\/doi.org\/10.1007\/s00432-023-05466-8.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"2080_CR166","doi-asserted-by":"publisher","first-page":"e780","DOI":"10.1055\/s-0043-1772590","volume":"45","author":"AE Santiago","year":"2023","unstructured":"Santiago AE, Paula SOCD, Carvalho ATD, C\u00e2ndido EB, Furtado RDS, Silva Filho ALD. Systemic inflammatory patterns in ovarian cancer patients: analysis of Cytokines, Chemokines, and microparticles. Rev Bras Ginecol Obstet. 2023;45(12):e780\u20139. https:\/\/doi.org\/10.1055\/s-0043-1772590.","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"10","key":"2080_CR167","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41416-022-01763-0","volume":"126","author":"S Seitz","year":"2022","unstructured":"Seitz S, Dreyer TF, Stange C, Steiger K, Br\u00e4uer R, Scheutz L, et al. CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. Br J Cancer. 2022;126(10):1470\u201380. https:\/\/doi.org\/10.1038\/s41416-022-01763-0.","journal-title":"Br J Cancer"},{"key":"2080_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166","author":"DA Bell","year":"2011","unstructured":"Bell DA, Bell DA, Berchuck A, Berchuck A, Birrer MJ, Birrer MJ, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011. https:\/\/doi.org\/10.1038\/nature10166.","journal-title":"Nature"},{"key":"2080_CR169","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13048-023-01286-z","volume":"16","author":"H Zheng","year":"2023","unstructured":"Zheng H, Guan X, Meng X, Tong Y, Wang Y, Xie S, et al. IFN-\u03b3 in ovarian tumor microenvironment upregulates HLA-E expression and predicts a poor prognosis. J Ovarian Res. 2023;16:229. https:\/\/doi.org\/10.1186\/s13048-023-01286-z.","journal-title":"J Ovarian Res"},{"issue":"1","key":"2080_CR170","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13048-023-01192-4","volume":"16","author":"P Kumar","year":"2023","unstructured":"Kumar P, Ranmale S, Mehta S, Tongaonkar H, Patel V, Singh AK, et al. Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer. J Ovarian Res. 2023;16(1):114. https:\/\/doi.org\/10.1186\/s13048-023-01192-4.","journal-title":"J Ovarian Res"},{"issue":"1","key":"2080_CR171","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1186\/s12967-025-06508-0","volume":"23","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhu N, Liu J, Chen F, Song Y, Ma Y, et al. Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements. J Translational Med. 2025;23(1):539. https:\/\/doi.org\/10.1186\/s12967-025-06508-0.","journal-title":"J Translational Med"},{"issue":"1","key":"2080_CR172","doi-asserted-by":"publisher","first-page":"2198185","DOI":"10.1080\/2162402X.2023.2198185","volume":"12","author":"PG Pavicic","year":"2023","unstructured":"Pavicic PG, Rayman PA, Swaidani S, Rupani A, Makarov V, Tannenbaum CS, et al. Immunotherapy with IL12 and PD1\/CTLA4 Inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression. Oncoimmunology. 2023;12(1):2198185. https:\/\/doi.org\/10.1080\/2162402X.2023.2198185.","journal-title":"Oncoimmunology"},{"key":"2080_CR173","doi-asserted-by":"publisher","first-page":"8797683","DOI":"10.1155\/2020\/8797683","volume":"2020","author":"M Bilska","year":"2020","unstructured":"Bilska M, Paw\u0142owska A, Zakrzewska E, Chudzik A, Suszczyk D, Gogacz M, et al. Th17 cells and IL-17 as novel immune targets in ovarian cancer therapy. J Oncol. 2020;2020:8797683. https:\/\/doi.org\/10.1155\/2020\/8797683.","journal-title":"J Oncol"},{"issue":"26","key":"2080_CR174","doi-asserted-by":"publisher","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","volume":"187","author":"G Mollaoglu","year":"2024","unstructured":"Mollaoglu G, Tepper A, Falcomat\u00e0 C, Potak HT, Pia L, Amabile A, et al. Ovarian cancer-derived IL-4 promotes immunotherapy resistance. Cell. 2024;187(26):7492\u2013e751022. https:\/\/doi.org\/10.1016\/j.cell.2024.10.006.","journal-title":"Cell"},{"issue":"10","key":"2080_CR175","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3390\/cancers17101691","volume":"17","author":"H Amer","year":"2025","unstructured":"Amer H, Flanagan KL, Kampan NC, Itsiopoulos C, Scott CL, Kartikasari AER, et al. Interleukin-6 is a crucial factor in shaping the inflammatory tumor microenvironment in ovarian cancer and determining its hot or cold nature with diagnostic and prognostic utilities. Cancers (Basel). 2025;17(10):1691. https:\/\/doi.org\/10.3390\/cancers17101691.","journal-title":"Cancers (Basel)"},{"key":"2080_CR176","doi-asserted-by":"publisher","first-page":"6455704","DOI":"10.1155\/2023\/6455704","volume":"2023","author":"X Wu","year":"2023","unstructured":"Wu X, Lu W, Xu C, Jiang C, Zhuo Z, Wang R, et al. Macrophages phenotype regulated by IL-6 are associated with the prognosis of platinum-resistant serous ovarian cancer: integrated analysis of clinical trial and omics. J Immunol Res. 2023;2023:6455704. https:\/\/doi.org\/10.1155\/2023\/6455704.","journal-title":"J Immunol Res"},{"key":"2080_CR177","doi-asserted-by":"publisher","first-page":"1448041","DOI":"10.3389\/fimmu.2024.1448041","volume":"15","author":"RJA Maas","year":"2024","unstructured":"Maas RJA, Hoogstad-van Evert JS, Hagemans IM, Brummelman J, van Ens D, de Jonge PKJD, et al. Increased peritoneal TGF-\u03b21 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer. Front Immunol. 2024;15:1448041. https:\/\/doi.org\/10.3389\/fimmu.2024.1448041.","journal-title":"Front Immunol"},{"issue":"4","key":"2080_CR178","doi-asserted-by":"publisher","first-page":"189374","DOI":"10.1016\/j.bbcan.2025.189374","volume":"1880","author":"E Grillo","year":"2025","unstructured":"Grillo E, Romani C, Ettorre VM, Santin AD, Mitola S. The VEGF\/VEGFR2 system in ovarian cancer: from functional to pharmacological significance. Biochim Biophys Acta (BBA) Rev Cancer. 2025;1880(4):189374. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189374.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"issue":"2","key":"2080_CR179","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","volume":"23","author":"N Horikawa","year":"2017","unstructured":"Horikawa N, Abiko K, Matsumura N, Hamanishi J, Baba T, Yamaguchi K, et al. Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res. 2017;23(2):587\u201399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0387.","journal-title":"Clin Cancer Res"},{"key":"2080_CR180","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12967-024-05085-y","volume":"22","author":"S Feng","year":"2024","unstructured":"Feng S, Ding B, Dai Z, Yin H, Ding Y, Liu S, et al. Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter. J Transl Med. 2024;22:280. https:\/\/doi.org\/10.1186\/s12967-024-05085-y.","journal-title":"J Transl Med"},{"issue":"3","key":"2080_CR181","doi-asserted-by":"publisher","first-page":"188888","DOI":"10.1016\/j.bbcan.2023.188888","volume":"1878","author":"V Bhardwaj","year":"2023","unstructured":"Bhardwaj V, Zhang X, Pandey V, Garg M. Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer. Biochim Biophys Acta (BBA) Rev Cancer. 2023;1878(3):188888. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188888.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"issue":"4","key":"2080_CR182","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3390\/cancers15041282","volume":"15","author":"S Oncul","year":"2023","unstructured":"Oncul S, Cho MS. Interactions between platelets and tumor microenvironment components in ovarian cancer and their implications for treatment and clinical outcomes. Cancers. 2023;15(4):1282. https:\/\/doi.org\/10.3390\/cancers15041282.","journal-title":"Cancers"},{"key":"2080_CR183","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-015-0366-5","volume":"14","author":"W Wen","year":"2015","unstructured":"Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh M-Y, et al. Synergistic anti-tumor effect of combined Inhibition of EGFR and JAK\/STAT3 pathways in human ovarian cancer. Mol Cancer. 2015;14:100. https:\/\/doi.org\/10.1186\/s12943-015-0366-5.","journal-title":"Mol Cancer"},{"issue":"6","key":"2080_CR184","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/cyto.2002.1022","volume":"17","author":"TM Savarese","year":"2002","unstructured":"Savarese TM, Campbell CL, McQuain C, Mitchell K, Guardiani R, Quesenberry PJ. Coexpression of oncostatin m and its receptors and evidence for STAT3 activation in human ovarian carcinomas. Cytokine. 2002;17(6):324\u201334. https:\/\/doi.org\/10.1006\/cyto.2002.1022.","journal-title":"Cytokine"},{"key":"2080_CR185","doi-asserted-by":"publisher","unstructured":"Arora N, Ahmed N, Luwor B. The potential role of Interleukin-11 in epithelial ovarian cancer. J Cancer Sci Clin Ther. 2019;03(01). https:\/\/doi.org\/10.26502\/jcsct.5079017.","DOI":"10.26502\/jcsct.5079017"},{"issue":"5","key":"2080_CR186","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.molcel.2014.05.015","volume":"54","author":"H Easwaran","year":"2014","unstructured":"Easwaran H, Tsai H-C, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716. https:\/\/doi.org\/10.1016\/j.molcel.2014.05.015.","journal-title":"Mol Cell"},{"issue":"2","key":"2080_CR187","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbcan.2016.04.001","volume":"1865","author":"A Kazanets","year":"2016","unstructured":"Kazanets A, Shorstova T, Hilmi K, Marques M, Witcher M. Epigenetic Silencing of tumor suppressor genes: paradigms, puzzles, and potential. Biochim Biophys Acta (BBA) Rev Cancer. 2016;1865(2):275\u201388. https:\/\/doi.org\/10.1016\/j.bbcan.2016.04.001.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"issue":"3","key":"2080_CR188","doi-asserted-by":"publisher","first-page":"e202400183","DOI":"10.1002\/bies.202400183","volume":"47","author":"J-P Capp","year":"2025","unstructured":"Capp J-P, Aliaga B, Pancaldi V. Evidence of epigenetic oncogenesis: A turning point in cancer research. BioEssays. 2025;47(3):e202400183. https:\/\/doi.org\/10.1002\/bies.202400183.","journal-title":"BioEssays"},{"key":"2080_CR189","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1007\/s12672-025-04085-8","volume":"16","author":"CX Ng","year":"2025","unstructured":"Ng CX, Lee SY, Yap XY, Wong YH, Loh JS, Ang KP, et al. Epigenetic reprogramming as the nexus of cancer stemness and therapy resistance: implications for biomarker discovery. Discov Oncol. 2025;16:2220. https:\/\/doi.org\/10.1007\/s12672-025-04085-8.","journal-title":"Discov Oncol"},{"issue":"5","key":"2080_CR190","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3390\/cancers14051221","volume":"14","author":"B Vezzani","year":"2022","unstructured":"Vezzani B, Carinci M, Previati M, Giacovazzi S, Della Sala M, Gaf\u00e0 R, et al. Epigenetic regulation: a link between inflammation and carcinogenesis. Cancers. 2022;14(5):1221. https:\/\/doi.org\/10.3390\/cancers14051221.","journal-title":"Cancers"},{"key":"2080_CR191","doi-asserted-by":"publisher","first-page":"931493","DOI":"10.3389\/fcell.2022.931493","volume":"10","author":"SYX Tan","year":"2022","unstructured":"Tan SYX, Zhang J, Tee W-W. Epigenetic regulation of inflammatory signaling and inflammation-Induced cancer. Front Cell Dev Biol. 2022;10:931493. https:\/\/doi.org\/10.3389\/fcell.2022.931493.","journal-title":"Front Cell Dev Biol"},{"key":"2080_CR192","doi-asserted-by":"publisher","unstructured":"Mafi S, Mansoori B, Taeb S, Sadeghi H, Abbasi R, Cho WC, et al. mTOR-Mediated regulation of immune responses in cancer and tumor microenvironment. Front Immunol. 2022;12. https:\/\/doi.org\/10.3389\/fimmu.2021.774103.","DOI":"10.3389\/fimmu.2021.774103"},{"issue":"28","key":"2080_CR193","doi-asserted-by":"publisher","first-page":"26457","DOI":"10.18632\/oncotarget.4762","volume":"6","author":"S Xu","year":"2015","unstructured":"Xu S, Fu G-B, Tao Z, OuYang J, Kong F, Jiang B-H, et al. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR\/P70S6K1. Oncotarget. 2015;6(28):26457\u201371.","journal-title":"Oncotarget"},{"issue":"6","key":"2080_CR194","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.cellsig.2012.02.007","volume":"24","author":"R Huber","year":"2012","unstructured":"Huber R, Pietsch D, Panterodt T, Brand K. Regulation of C\/EBP\u03b2 and resulting functions in cells of the monocytic lineage. Cell Signal. 2012;24(6):1287\u201396. https:\/\/doi.org\/10.1016\/j.cellsig.2012.02.007.","journal-title":"Cell Signal"},{"issue":"1","key":"2080_CR195","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/s41467-018-03590-5","volume":"9","author":"D Liu","year":"2018","unstructured":"Liu D, Zhang X-X, Li M-C, Cao C-H, Wan D-Y, Xi B-X, et al. C\/EBP\u03b2 enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun. 2018;9(1):1739. https:\/\/doi.org\/10.1038\/s41467-018-03590-5.","journal-title":"Nat Commun"},{"issue":"2","key":"2080_CR196","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/mc.23843","volume":"64","author":"L-Y Chen","year":"2025","unstructured":"Chen L-Y, Yang S-Y, Chou J-L, Chou H-L, Yeh C-C, Chiu C-C, et al. The role of SMAD7 in the epigenetic regulation of TGF-\u03b2 targets in the metastasis of ovarian cancer. Mol Carcinog. 2025;64(2):290\u2013304. https:\/\/doi.org\/10.1002\/mc.23843.","journal-title":"Mol Carcinog"},{"issue":"1","key":"2080_CR197","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41598-023-28840-5","volume":"13","author":"S Sato","year":"2023","unstructured":"Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, et al. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Sci Rep. 2023;13(1):1537. https:\/\/doi.org\/10.1038\/s41598-023-28840-5.","journal-title":"Sci Rep"},{"issue":"4","key":"2080_CR198","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/0008-5472.CAN-18-2297","volume":"79","author":"J Hooda","year":"2019","unstructured":"Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, MacDuffie E, et al. Early loss of histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res. 2019;79(4):760\u201372. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2297.","journal-title":"Cancer Res"},{"issue":"4","key":"2080_CR199","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/or.2021.7994","volume":"45","author":"J Chen","year":"2021","unstructured":"Chen J, Chen H, Pan L. SIRT1 and gynecological malignancies (Review). Oncol Rep. 2021;45(4):43. https:\/\/doi.org\/10.3892\/or.2021.7994.","journal-title":"Oncol Rep"},{"key":"2080_CR200","doi-asserted-by":"publisher","first-page":"831168","DOI":"10.3389\/fimmu.2022.831168","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Liu Y, Wang Y, Chao Y, Zhang J, Jia Y, et al. Regulation of SIRT1 and its roles in inflammation. Front Immunol. 2022;13:831168. https:\/\/doi.org\/10.3389\/fimmu.2022.831168.","journal-title":"Front Immunol"},{"issue":"8","key":"2080_CR201","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/2211-5463.13624","volume":"13","author":"B Gaire","year":"2023","unstructured":"Gaire B, Padmanabhan S, Zou Y, Uddin MM, Reddy SU, Vancurova I. IFN\u03b3 induces Bcl3 expression by JAK1\/STAT1\/p65 signaling, resulting in increased IL-8 expression in ovarian cancer cells. FEBS Open Bio. 2023;13(8):1495\u2013506. https:\/\/doi.org\/10.1002\/2211-5463.13624.","journal-title":"FEBS Open Bio"},{"issue":"1","key":"2080_CR202","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/07357907.2024.2430283","volume":"43","author":"X Hu","year":"2025","unstructured":"Hu X, Huang Z, Li L. LDHB mediates histone lactylation to activate PD-L1 and promote ovarian cancer immune escape. Cancer Invest. 2025;43(1):70\u20139. https:\/\/doi.org\/10.1080\/07357907.2024.2430283.","journal-title":"Cancer Invest"},{"issue":"1","key":"2080_CR203","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13048-024-01358-8","volume":"17","author":"H Yang","year":"2024","unstructured":"Yang H, Sui L, Cai C, Chu H, Diao Y. SETDB1 promotes progression through upregulation of SF3B4 expression and regulates the immunity in ovarian cancer. J Ovarian Res. 2024;17(1):34. https:\/\/doi.org\/10.1186\/s13048-024-01358-8.","journal-title":"J Ovarian Res"},{"issue":"3","key":"2080_CR204","doi-asserted-by":"publisher","first-page":"540","DOI":"10.4049\/jimmunol.1901277","volume":"206","author":"A Boucher","year":"2021","unstructured":"Boucher A, Klopfenstein N, Hallas WM, Skibbe J, Appert A, Jang SH, et al. The miR-23a\u223c27a\u223c24\u2009\u2013\u20092 MicroRNA cluster promotes inflammatory polarization of macrophages. J Immunol. 2021;206(3):540\u201353. https:\/\/doi.org\/10.4049\/jimmunol.1901277.","journal-title":"J Immunol"},{"issue":"5","key":"2080_CR205","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00018-022-04250-0","volume":"79","author":"L Fan","year":"2022","unstructured":"Fan L, Lei H, Lin Y, Zhou Z, Li J, Wu A, et al. Hotair promotes the migration and proliferation in ovarian cancer by miR-222-3p\/CDK19 axis. Cell Mol Life Sci. 2022;79(5):254. https:\/\/doi.org\/10.1007\/s00018-022-04250-0.","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"2080_CR206","doi-asserted-by":"publisher","first-page":"e0178937","DOI":"10.1371\/journal.pone.0178937","volume":"12","author":"K-T Lin","year":"2017","unstructured":"Lin K-T, Sun S-P, Wu J-I, Wang L-H. D <>Nie editor 2017 Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model. PLoS ONE 12 6 e0178937 https:\/\/doi.org\/10.1371\/journal.pone.0178937.","journal-title":"PLoS ONE"},{"issue":"5","key":"2080_CR207","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s10753-019-01004-2","volume":"42","author":"B Jiang","year":"2019","unstructured":"Jiang B, Zhu S-J, Xiao S-S, Xue M. MiR-217 inhibits M2-Like macrophage polarization by suppressing secretion of Interleukin-6 in ovarian cancer. Inflammation. 2019;42(5):1517\u201329. https:\/\/doi.org\/10.1007\/s10753-019-01004-2.","journal-title":"Inflammation"},{"key":"2080_CR208","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2017.11.026","volume":"415","author":"Z Yang","year":"2018","unstructured":"Yang Z, Jin P, Xu S, Zhang T, Yang X, Li X, et al. Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer. Cancer Lett. 2018;415:20\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2017.11.026.","journal-title":"Cancer Lett"},{"issue":"12","key":"2080_CR209","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1038\/cdd.2017.129","volume":"24","author":"Y Wang","year":"2017","unstructured":"Wang Y, Zhang X, Tang W, Lin Z, Xu L, Dong R, et al. miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-\u03baB in high-grade serous ovarian carcinoma. Cell Death Differ. 2017;24(12):2089\u2013100. https:\/\/doi.org\/10.1038\/cdd.2017.129.","journal-title":"Cell Death Differ"},{"issue":"19","key":"2080_CR210","doi-asserted-by":"publisher","first-page":"10201","DOI":"10.3390\/ijms221910201","volume":"22","author":"T-L Mao","year":"2021","unstructured":"Mao T-L, Fan M-H, Dlamini N, Liu C-L. LncRNA MALAT1 facilitates ovarian cancer progression through promoting chemoresistance and invasiveness in the tumor microenvironment. IJMS. 2021;22(19):10201. https:\/\/doi.org\/10.3390\/ijms221910201.","journal-title":"IJMS"},{"issue":"7","key":"2080_CR211","doi-asserted-by":"publisher","first-page":"11949","DOI":"10.1002\/jcb.28478","volume":"120","author":"X Chen","year":"2019","unstructured":"Chen X, Wu W, Cao X, Zhao X, Li W, Deng C, et al. LncRNA mortal obligate RNA transcript was downregulated in ovarian carcinoma and inhibits cancer cell proliferation by downregulating miRNA-21. J Cell Biochem. 2019;120(7):11949\u201354. https:\/\/doi.org\/10.1002\/jcb.28478.","journal-title":"J Cell Biochem"},{"issue":"15","key":"2080_CR212","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.3390\/ijms22157829","volume":"22","author":"R Di Fiore","year":"2021","unstructured":"Di Fiore R, Suleiman S, Drago-Ferrante R, Felix A, O\u2019Toole SA, O\u2019Leary JJ, et al. LncRNA MORT (ZNF667-AS1) in Cancer\u2014Is there a possible role in gynecological malignancies? IJMS. 2021;22(15):7829. https:\/\/doi.org\/10.3390\/ijms22157829.","journal-title":"IJMS"},{"issue":"5","key":"2080_CR213","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3892\/etm.2025.12850","volume":"29","author":"F Wu","year":"2025","unstructured":"Wu F, Zhang T, Mei X, Gao T. LncRNA ZNF667\u2013AS1 inhibits ovarian cancer progression by interacting with the TNF signaling pathway. Exp Ther Med. 2025;29(5):100. https:\/\/doi.org\/10.3892\/etm.2025.12850.","journal-title":"Exp Ther Med"},{"key":"2080_CR214","doi-asserted-by":"publisher","first-page":"727876","DOI":"10.3389\/fphar.2021.727876","volume":"12","author":"F Guo","year":"2021","unstructured":"Guo F, Du J, Liu L, Gou Y, Zhang M, Sun W, et al. LncRNA OR3A4 promotes the proliferation and metastasis of ovarian cancer through KLF6 pathway. Front Pharmacol. 2021;12:727876. https:\/\/doi.org\/10.3389\/fphar.2021.727876.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2080_CR215","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1186\/s12967-023-04762-8","volume":"21","author":"Y Chen","year":"2023","unstructured":"Chen Y, He Z, Yang S, Chen C, Xiong W, He Y, et al. RUNX1 knockdown induced apoptosis and impaired EMT in high-grade serous ovarian cancer cells. J Translational Med. 2023;21(1):886. https:\/\/doi.org\/10.1186\/s12967-023-04762-8.","journal-title":"J Translational Med"},{"issue":"6","key":"2080_CR216","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41388-023-02910-4","volume":"43","author":"X Yu","year":"2024","unstructured":"Yu X, Zhao P, Luo Q, Wu X, Wang Y, Nan Y, et al. RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-\u03baB activation and ovarian cancer progression. Oncogene. 2024;43(6):420\u201333. https:\/\/doi.org\/10.1038\/s41388-023-02910-4.","journal-title":"Oncogene"},{"issue":"1","key":"2080_CR217","doi-asserted-by":"publisher","first-page":"17996","DOI":"10.1038\/s41598-019-54401-w","volume":"9","author":"HD Reyes","year":"2019","unstructured":"Reyes HD, Devor EJ, Warrier A, Newtson AM, Mattson J, Wagner V, et al. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior. Sci Rep. 2019;9(1):17996. https:\/\/doi.org\/10.1038\/s41598-019-54401-w.","journal-title":"Sci Rep"},{"key":"2080_CR218","doi-asserted-by":"publisher","unstructured":"Gilchrist JJ, Fang H, Danielli S, Tomkova M, Nassiri I, Ng E, et al. Characterization of the genetic determinants of context-specific DNA methylation in primary monocytes. Cell Genomics. 2024;4(5). https:\/\/doi.org\/10.1016\/j.xgen.2024.100541.","DOI":"10.1016\/j.xgen.2024.100541"},{"issue":"6","key":"2080_CR219","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2024.5650","volume":"64","author":"M Fu","year":"2024","unstructured":"Fu M, Deng F, Chen J, Fu L, Lei J, Xu T, et al. Current data and future perspectives on DNA methylation in ovarian cancer (Review). Int J Oncol. 2024;64(6):1\u201319. https:\/\/doi.org\/10.3892\/ijo.2024.5650.","journal-title":"Int J Oncol"},{"issue":"1","key":"2080_CR220","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3892\/ol.2016.4608","volume":"12","author":"B Yan","year":"2016","unstructured":"Yan B, Yin F, Wang Q, Zhang W, Li L. Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer. Oncol Lett. 2016;12(1):157\u201366. https:\/\/doi.org\/10.3892\/ol.2016.4608.","journal-title":"Oncol Lett"},{"issue":"3","key":"2080_CR221","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/1055-9965.EPI-16-0461","volume":"26","author":"DC Koestler","year":"2017","unstructured":"Koestler DC, Usset J, Christensen BC, Marsit CJ, Karagas MR, Kelsey KT, et al. DNA methylation-derived neutrophil-to-lymphocyte ratio: an epigenetic tool to explore cancer inflammation and outcomes. Cancer Epidemiol Biomarkers Prev. 2017;26(3):328\u201338. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-0461.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"20","key":"2080_CR222","doi-asserted-by":"publisher","first-page":"15066","DOI":"10.3390\/ijms242015066","volume":"24","author":"L Xu","year":"2023","unstructured":"Xu L, Yan X, Wang J, Zhao Y, Liu Q, Fu J, et al. The roles of histone deacetylases in the regulation of ovarian cancer metastasis. Int J Mol Sci. 2023;24(20):15066. https:\/\/doi.org\/10.3390\/ijms242015066.","journal-title":"Int J Mol Sci"},{"key":"2080_CR223","doi-asserted-by":"publisher","first-page":"1057186","DOI":"10.3389\/fonc.2022.1057186","volume":"12","author":"F Guo","year":"2022","unstructured":"Guo F, Wang H. Potential of histone deacetylase inhibitors for the therapy of ovarian cancer. Front Oncol. 2022;12:1057186. https:\/\/doi.org\/10.3389\/fonc.2022.1057186.","journal-title":"Front Oncol"},{"issue":"21","key":"2080_CR224","doi-asserted-by":"publisher","first-page":"11496","DOI":"10.3390\/ijms222111496","volume":"22","author":"L Pascual-Ant\u00f3n","year":"2021","unstructured":"Pascual-Ant\u00f3n L, Carde\u00f1es B, De La Sainz R, Gonz\u00e1lez-Cortijo L, L\u00f3pez-Cabrera M, Caba\u00f1as C, et al. Mesothelial-to-mesenchymal transition and exosomes in peritoneal metastasis of ovarian cancer. IJMS. 2021;22(21):11496. https:\/\/doi.org\/10.3390\/ijms222111496.","journal-title":"IJMS"},{"issue":"5","key":"2080_CR225","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3892\/ijo.2016.3442","volume":"48","author":"B Zhou","year":"2016","unstructured":"Zhou B, Sun C, Li N, Shan W, Lu H, Guo L, et al. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K\/Akt signaling pathways. Int J Oncol. 2016;48(5):2087\u201397. https:\/\/doi.org\/10.3892\/ijo.2016.3442.","journal-title":"Int J Oncol"},{"issue":"3","key":"2080_CR226","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ygyno.2009.08.031","volume":"115","author":"S Aggarwal","year":"2009","unstructured":"Aggarwal S, He T, FitzHugh W, Rosenthal K, Feild B, Heidbrink J, et al. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer. Gynecol Oncol. 2009;115(3):430\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2009.08.031.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2080_CR227","doi-asserted-by":"publisher","first-page":"188639","DOI":"10.1016\/j.bbcan.2021.188639","volume":"1876","author":"I Szulc-Kielbik","year":"2021","unstructured":"Szulc-Kielbik I, Kielbik M, Nowak M, Klink M. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. Biochim Biophys Acta (BBA) Rev Cancer. 2021;1876(2):188639. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188639.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"issue":"32","key":"2080_CR228","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2217\/fon-2020-0095","volume":"16","author":"F Zhang","year":"2020","unstructured":"Zhang F, Cui J, Gao H, Yu H, Gao F, Chen J, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12\/CXCR4 axis. Future Oncol. 2020;16(32):2619\u201333. https:\/\/doi.org\/10.2217\/fon-2020-0095.","journal-title":"Future Oncol"},{"issue":"2","key":"2080_CR229","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cyto.2011.06.005","volume":"56","author":"Y Wang","year":"2011","unstructured":"Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine. 2011;56(2):365\u201375. https:\/\/doi.org\/10.1016\/j.cyto.2011.06.005.","journal-title":"Cytokine"},{"issue":"10","key":"2080_CR230","doi-asserted-by":"publisher","first-page":"13405","DOI":"10.18632\/aging.203074","volume":"13","author":"TB Henriques","year":"2021","unstructured":"Henriques TB, dos Santos DZ, dos Santos Guimar\u00e3es I, Tessarollo NG, Lyra-Junior PCM, Mesquita P, et al. Inhibition of CXCR2 plays a pivotal role in re-sensitizing ovarian cancer to cisplatin treatment. Aging. 2021;13(10):13405\u201320. https:\/\/doi.org\/10.18632\/aging.203074.","journal-title":"Aging"},{"issue":"2","key":"2080_CR231","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ejca.2012.06.026","volume":"49","author":"S Marchini","year":"2013","unstructured":"Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer. 2013;49(2):520\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2012.06.026.","journal-title":"Eur J Cancer"},{"issue":"9","key":"2080_CR232","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1038\/oncsis.2012.25","volume":"1","author":"P Wojnarowicz","year":"2012","unstructured":"Wojnarowicz P, Gambaro K, de Ladurantaye M, Quinn MCJ, Provencher D, Mes-Masson A-M, et al. Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity. Oncogenesis. 2012;1(9):e27\u201327. https:\/\/doi.org\/10.1038\/oncsis.2012.25.","journal-title":"Oncogenesis"},{"issue":"1","key":"2080_CR233","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12672-025-02509-z","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Tang T, Sun Y, Chen G, Yuan X, Cai D. The role of TLR-4 in chemoresistance of cancer. Discov Onc. 2025;16(1):865. https:\/\/doi.org\/10.1007\/s12672-025-02509-z.","journal-title":"Discov Onc"},{"issue":"1","key":"2080_CR234","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12094-021-02668-9","volume":"24","author":"AH Gao","year":"2022","unstructured":"Gao AH, Hu YR, Zhu WP. IFN-\u03b3 inhibits ovarian cancer progression via SOCS1\/JAK\/STAT signaling pathway. Clin Transl Oncol. 2022;24(1):57\u201365. https:\/\/doi.org\/10.1007\/s12094-021-02668-9.","journal-title":"Clin Transl Oncol"},{"key":"2080_CR235","doi-asserted-by":"publisher","first-page":"104434","DOI":"10.1016\/j.critrevonc.2024.104434","volume":"201","author":"I Miras","year":"2024","unstructured":"Miras I, Est\u00e9vez-Garc\u00eda P, Mu\u00f1oz-Galv\u00e1n S. Clinical and molecular features of platinum resistance in ovarian cancer. Crit Rev Oncol\/Hematol. 2024;201:104434. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104434.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"3","key":"2080_CR236","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/medicina59030544","volume":"59","author":"A Havasi","year":"2023","unstructured":"Havasi A, Cainap SS, Havasi AT, Cainap C. Ovarian cancer\u2014insights into platinum resistance and overcoming it. Medicina. 2023;59(3):544. https:\/\/doi.org\/10.3390\/medicina59030544.","journal-title":"Medicina"},{"issue":"5","key":"2080_CR237","doi-asserted-by":"publisher","first-page":"518","DOI":"10.2174\/1381612822666151124234417","volume":"22","author":"M Ghandadi","year":"2016","unstructured":"Ghandadi M, Sahebkar A. Interleukin-6: a critical cytokine in cancer multidrug resistance. CPD. 2016;22(5):518\u201326. https:\/\/doi.org\/10.2174\/1381612822666151124234417.","journal-title":"CPD"},{"issue":"9","key":"2080_CR238","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","volume":"9","author":"MB Meads","year":"2009","unstructured":"Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9(9):665\u201374. https:\/\/doi.org\/10.1038\/nrc2714.","journal-title":"Nat Rev Cancer"},{"key":"2080_CR239","doi-asserted-by":"publisher","first-page":"115036","DOI":"10.1016\/j.biopha.2023.115036","volume":"165","author":"X Zhou","year":"2023","unstructured":"Zhou X, An B, Lin Y, Ni Y, Zhao X, Liang X. Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies. Biomed Pharmacother. 2023;165:115036. https:\/\/doi.org\/10.1016\/j.biopha.2023.115036.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2080_CR240","doi-asserted-by":"publisher","first-page":"3907147","DOI":"10.1155\/2016\/3907147","volume":"2016","author":"M Tafani","year":"2016","unstructured":"Tafani M, Sansone L, Limana F, Arcangeli T, De Santis E, Polese M, et al. The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. Oxidative Med Cell Longev. 2016;2016(1):3907147. https:\/\/doi.org\/10.1155\/2016\/3907147.","journal-title":"Oxidative Med Cell Longev"},{"issue":"36","key":"2080_CR241","doi-asserted-by":"publisher","first-page":"60299","DOI":"10.18632\/oncotarget.19140","volume":"8","author":"B Kim","year":"2017","unstructured":"Kim B, Jung JW, Jung J, Han Y, Suh DH, Kim HS, et al. PGC1\u03b1 induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells. Oncotarget. 2017;8(36):60299\u2013311. https:\/\/doi.org\/10.18632\/oncotarget.19140.","journal-title":"Oncotarget"},{"issue":"11","key":"2080_CR242","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.3390\/cells10113213","volume":"10","author":"A Ferraresi","year":"2021","unstructured":"Ferraresi A, Esposito A, Girone C, Vallino L, Salwa A, Ghezzi I, et al. Resveratrol contrasts LPA-Induced ovarian cancer cell migration and platinum resistance by rescuing hedgehog-mediated autophagy. Cells. 2021;10(11):3213. https:\/\/doi.org\/10.3390\/cells10113213.","journal-title":"Cells"},{"issue":"10","key":"2080_CR243","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/cells8101143","volume":"8","author":"GS Markopoulos","year":"2019","unstructured":"Markopoulos GS, Roupakia E, Marcu KB, Kolettas E. Epigenetic regulation of inflammatory cytokine-induced epithelial-to-mesenchymal cell transition and cancer stem cell generation. Cells. 2019;8(10):1143. https:\/\/doi.org\/10.3390\/cells8101143.","journal-title":"Cells"},{"key":"2080_CR244","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2020.12.042","volume":"502","author":"V Bhardwaj","year":"2021","unstructured":"Bhardwaj V, Tan YQ, Wu MM, Ma L, Zhu T, Lobie PE, et al. Long non-coding RNAs in recurrent ovarian cancer: theranostic perspectives. Cancer Lett. 2021;502:97\u2013107. https:\/\/doi.org\/10.1016\/j.canlet.2020.12.042.","journal-title":"Cancer Lett"},{"key":"2080_CR245","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13048-025-01770-8","volume":"18","author":"R Nayak","year":"2025","unstructured":"Nayak R, Pandey S, Kumar D, Kumar S, Pai KSR. Signaling networks and MiRNA crosstalk in ovarian cancer chemoresistance. J Ovarian Res. 2025;18:185. https:\/\/doi.org\/10.1186\/s13048-025-01770-8.","journal-title":"J Ovarian Res"},{"issue":"1","key":"2080_CR246","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13148-021-01133-2","volume":"13","author":"L Feng","year":"2021","unstructured":"Feng L, Yan B, Huang Y, Li L. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer. Clin Epigenet. 2021;13(1):141. https:\/\/doi.org\/10.1186\/s13148-021-01133-2.","journal-title":"Clin Epigenet"},{"issue":"3","key":"2080_CR247","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13238-020-00796-6","volume":"12","author":"B Cong","year":"2021","unstructured":"Cong B, Zhang Q, Cao X. The function and regulation of TET2 in innate immunity and inflammation. Protein Cell. 2021;12(3):165\u201373. https:\/\/doi.org\/10.1007\/s13238-020-00796-6.","journal-title":"Protein Cell"},{"issue":"6","key":"2080_CR248","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/1078-0432.CCR-17-1958","volume":"24","author":"DW Tucker","year":"2018","unstructured":"Tucker DW, Getchell CR, McCarthy ET, Ohman AW, Sasamoto N, Xu S, et al. Epigenetic reprogramming strategies to reverse global loss of 5-Hydroxymethylcytosine, a prognostic factor for poor survival in High-grade serous ovarian cancer. Clin Cancer Res. 2018;24(6):1389\u2013401. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1958.","journal-title":"Clin Cancer Res"},{"key":"2080_CR249","doi-asserted-by":"publisher","first-page":"108334","DOI":"10.1016\/j.abb.2020.108334","volume":"684","author":"H Zhang","year":"2020","unstructured":"Zhang H, Wang Z, Wang F, Wang C, Zhang H. IL-6 and IL-8 are involved in JMJD2A-regulated malignancy of ovarian cancer cells. Arch Biochem Biophys. 2020;684:108334. https:\/\/doi.org\/10.1016\/j.abb.2020.108334.","journal-title":"Arch Biochem Biophys"},{"key":"2080_CR250","doi-asserted-by":"publisher","unstructured":"Mar\u00ed-Alexandre et al. Pell\u00edn Carcel\u00e9n, Agababyan, Moreno-Manuel, Garc\u00eda-Oms, Calabuig-Fari\u00f1as,. Interplay Between MicroRNAs and Oxidative Stress in Ovarian Conditions with a Focus on Ovarian Cancer and Endometriosis. IJMS. 2019;20(21):5322. https:\/\/doi.org\/10.3390\/ijms20215322","DOI":"10.3390\/ijms20215322"},{"key":"2080_CR251","doi-asserted-by":"publisher","first-page":"11150","DOI":"10.1038\/ncomms11150","volume":"7","author":"CL Au Yeung","year":"2016","unstructured":"Au Yeung CL, Co N-N, Tsuruga T, Yeung T-L, Kwan S-Y, Leung CS, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150. https:\/\/doi.org\/10.1038\/ncomms11150.","journal-title":"Nat Commun"},{"key":"2080_CR252","doi-asserted-by":"publisher","first-page":"1204033","DOI":"10.3389\/fcell.2023.1204033","volume":"11","author":"L Chen","year":"2023","unstructured":"Chen L, Jin X, Ma J, Xiang B, Li X. YAP at the progression of inflammation. Front Cell Dev Biol. 2023;11:1204033. https:\/\/doi.org\/10.3389\/fcell.2023.1204033.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"2080_CR253","doi-asserted-by":"publisher","first-page":"101519","DOI":"10.1016\/j.gendis.2025.101519","volume":"12","author":"C Liu","year":"2025","unstructured":"Liu C, Shi L, Meng Z, Zhang M, Zhang Z, Li Y, et al. Restriction of YWHAB-mediated YAP cytoplasmic retention is a novel mechanism underlying stemness maintenance and chemoresistance in ovarian cancer peritoneal metastasis. Genes Dis. 2025;12(5):101519. https:\/\/doi.org\/10.1016\/j.gendis.2025.101519.","journal-title":"Genes Dis"},{"issue":"1","key":"2080_CR254","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26599\/BSA.2022.9050008","volume":"8","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wang X, Zhou X. Functions of Yes-association protein (YAP) in cancer progression and anticancer therapy resistance. Brain Sci Adv. 2022;8(1):1\u201318. https:\/\/doi.org\/10.26599\/BSA.2022.9050008.","journal-title":"Brain Sci Adv"},{"key":"2080_CR255","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s43556-025-00373-5","volume":"6","author":"C Ma","year":"2025","unstructured":"Ma C, Cheng J, Gu J, Wang Q. Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications. Mol Biomed. 2025;6:132. https:\/\/doi.org\/10.1186\/s43556-025-00373-5.","journal-title":"Mol Biomed"},{"issue":"5","key":"2080_CR256","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-19-1638","volume":"26","author":"A Oza","year":"2020","unstructured":"Oza A, Matulonis U, Alvarez Secord A, Roman L, Blagden S, Banerjee S, et al. A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer. Clin Cancer Res. 2020;26(5):1009\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1638.","journal-title":"Clin Cancer Res"},{"key":"2080_CR257","doi-asserted-by":"publisher","unstructured":"Khabele D. The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Front Oncol. 2014;4. https:\/\/doi.org\/10.3389\/fonc.2014.00111.","DOI":"10.3389\/fonc.2014.00111"},{"issue":"2","key":"2080_CR258","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccell.2019.12.015","volume":"37","author":"S Karakashev","year":"2020","unstructured":"Karakashev S, Fukumoto T, Zhao B, Lin J, Wu S, Fatkhutdinov N, et al. EZH2 Inhibition sensitizes CARM1-high, homologous recombination proficient ovarian cancers to PARP Inhibition. Cancer Cell. 2020;37(2):157\u2013e1676. https:\/\/doi.org\/10.1016\/j.ccell.2019.12.015.","journal-title":"Cancer Cell"},{"issue":"4","key":"2080_CR259","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/1535-7163.MCT-21-0743","volume":"21","author":"P Spiliopoulou","year":"2022","unstructured":"Spiliopoulou P, Spear S, Mirza H, Garner I, McGarry L, Grundland-Freile F, et al. Dual G9A\/EZH2 inhibition stimulates antitumor immune response in ovarian high-grade serous carcinoma. Mol Cancer Ther. 2022;21(4):522\u201334. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0743.","journal-title":"Mol Cancer Ther"},{"key":"2080_CR260","doi-asserted-by":"publisher","first-page":"109539","DOI":"10.1016\/j.cellsig.2020.109539","volume":"68","author":"AA El-Arabey","year":"2020","unstructured":"El-Arabey AA, Denizli M, Kanlikilicer P, Bayraktar R, Ivan C, Rashed M, et al. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020;68:109539. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109539.","journal-title":"Cell Signal"},{"issue":"1","key":"2080_CR261","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00280-019-03988-y","volume":"85","author":"B Kashani","year":"2020","unstructured":"Kashani B, Zandi Z, Bashash D, Zaghal A, Momeny M, Poursani EM, et al. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid). Cancer Chemother Pharmacol. 2020;85(1):47\u201359. https:\/\/doi.org\/10.1007\/s00280-019-03988-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2080_CR262","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1124\/mol.118.111674","volume":"94","author":"M Alqinyah","year":"2018","unstructured":"Alqinyah M, Almutairi F, Wendimu MY, Hooks SB. RGS10 regulates the expression of cyclooxygenase-2 and tumor necrosis factor alpha through a G protein\u2013independent mechanism. Mol Pharmacol. 2018;94(4):1103\u201313. https:\/\/doi.org\/10.1124\/mol.118.111674.","journal-title":"Mol Pharmacol"},{"key":"2080_CR263","doi-asserted-by":"publisher","unstructured":"Cacan E, Ali MW, Boyd NH, Hooks SB, Greer SF. Inhibition of HDAC1 and DNMT1 Modulate RGS10 Expression and Decrease Ovarian Cancer Chemoresistance. Tansey MG, editor. PLoS ONE. 2014;9(1):e87455. https:\/\/doi.org\/10.1371\/journal.pone.0087455","DOI":"10.1371\/journal.pone.0087455"},{"issue":"11","key":"2080_CR264","doi-asserted-by":"publisher","first-page":"e004974","DOI":"10.1136\/jitc-2022-004974","volume":"10","author":"S Gomez","year":"2022","unstructured":"Gomez S, Cox OL, Walker RR, Rentia U, Hadley M, Arthofer E, et al. Inhibiting DNA methylation and RNA editing upregulates Immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer. J Immunother Cancer. 2022;10(11):e004974. https:\/\/doi.org\/10.1136\/jitc-2022-004974.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2080_CR265","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1038\/s41598-020-60409-4","volume":"10","author":"S Moufarrij","year":"2020","unstructured":"Moufarrij S, Srivastava A, Gomez S, Hadley M, Palmer E, Austin PT, et al. Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer. Sci Rep. 2020;10(1):3470. https:\/\/doi.org\/10.1038\/s41598-020-60409-4.","journal-title":"Sci Rep"},{"issue":"14","key":"2080_CR266","doi-asserted-by":"publisher","first-page":"e158800","DOI":"10.1172\/JCI158800","volume":"132","author":"S Chen","year":"2022","unstructured":"Chen S, Xie P, Cowan M, Huang H, Cardenas H, Keathley R, et al. Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. J Clin Invest. 2022;132(14):e158800. https:\/\/doi.org\/10.1172\/JCI158800.","journal-title":"J Clin Invest"},{"issue":"12","key":"2080_CR267","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1021\/acsptsci.3c00215","volume":"6","author":"JM Duda","year":"2023","unstructured":"Duda JM, Thomas SN. Interactions of histone deacetylase 6 with DNA damage repair factors strengthen its utility as a combination drug target in high-grade serous ovarian cancer. ACS Pharmacol Transl Sci. 2023;6(12):1924\u201333. https:\/\/doi.org\/10.1021\/acsptsci.3c00215.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"2080_CR268","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00280-023-04610-y","volume":"93","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wen J, Sun X, Sun Y, Liu Y, Cheng X, et al. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms. Cancer Chemother Pharmacol. 2024;93(4):295\u2013306. https:\/\/doi.org\/10.1007\/s00280-023-04610-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2080_CR269","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tips.2017.11.008","volume":"39","author":"I Vancurova","year":"2017","unstructured":"Vancurova I, Uddin MM, Zou Y, Vancura A. Combination therapies targeting HDAC, IKK in solid tumors. Trends Pharmacol Sci. 2017;39(3):295. https:\/\/doi.org\/10.1016\/j.tips.2017.11.008.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"2080_CR270","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1038\/s41598-024-52814-w","volume":"14","author":"T Abd El-Hafeez","year":"2024","unstructured":"Abd El-Hafeez T, Shams MY, Elshaier YAMM, Farghaly HM, Hassanien AE. Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs. Sci Rep. 2024;14(1):2428. https:\/\/doi.org\/10.1038\/s41598-024-52814-w.","journal-title":"Sci Rep"},{"key":"2080_CR271","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02641","author":"EN Bergstrom","year":"2024","unstructured":"Bergstrom EN, Abbasi A, D\u00edaz-Gay M, Galland L, Ladoire S, Lippman SM, et al. Deep learning artificial intelligence predicts homologous recombination deficiency and platinum response from histologic slides. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.23.02641.","journal-title":"J Clin Oncol"},{"key":"2080_CR272","doi-asserted-by":"publisher","unstructured":"Wu Q, Tian R, He X, Liu J, Ou C, Li Y, et al. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1164408.","DOI":"10.3389\/fimmu.2023.1164408"},{"issue":"6","key":"2080_CR273","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s43018-022-00388-9","volume":"3","author":"KM Boehm","year":"2022","unstructured":"Boehm KM, Aherne EA, Ellenson L, Nikolovski I, Alghamdi M, V\u00e1zquez-Garc\u00eda I, et al. Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nat Cancer. 2022;3(6):723\u201333. https:\/\/doi.org\/10.1038\/s43018-022-00388-9.","journal-title":"Nat Cancer"},{"key":"2080_CR274","doi-asserted-by":"publisher","first-page":"e48527","DOI":"10.2196\/48527","volume":"26","author":"Q Wang","year":"2024","unstructured":"Wang Q, Chang Z, Liu X, Wang Y, Feng C, Ping Y, et al. Predictive value of machine learning for platinum chemotherapy responses in ovarian cancer: systematic review and meta-analysis. J Med Internet Res. 2024;26:e48527. https:\/\/doi.org\/10.2196\/48527.","journal-title":"J Med Internet Res"},{"issue":"1","key":"2080_CR275","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1038\/s41598-022-06788-2","volume":"12","author":"F Farinella","year":"2022","unstructured":"Farinella F, Merone M, Bacco L, Capirchio A, Ciccozzi M, Caligiore D. Machine learning analysis of high-grade serous ovarian cancer proteomic dataset reveals novel candidate biomarkers. Sci Rep. 2022;12(1):3041. https:\/\/doi.org\/10.1038\/s41598-022-06788-2.","journal-title":"Sci Rep"},{"key":"2080_CR276","doi-asserted-by":"publisher","first-page":"852746","DOI":"10.3389\/fonc.2022.852746","volume":"12","author":"V Bhardwaj","year":"2022","unstructured":"Bhardwaj V, Sharma A, Parambath SV, Gul I, Zhang X, Lobie PE, et al. Machine learning for endometrial cancer prediction and prognostication. Front Oncol. 2022;12:852746. https:\/\/doi.org\/10.3389\/fonc.2022.852746.","journal-title":"Front Oncol"},{"key":"2080_CR277","doi-asserted-by":"publisher","unstructured":"Zhao F, Jiang X, Li Y, Huang T, Xiahou Z, Nie W, et al. Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategies. Front Immunol. 2025;15. https:\/\/doi.org\/10.3389\/fimmu.2024.1500153.","DOI":"10.3389\/fimmu.2024.1500153"},{"issue":"21","key":"2080_CR278","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1158\/0008-5472.CAN-21-3819","volume":"82","author":"Y Wang","year":"2022","unstructured":"Wang Y, Xie H, Chang X, Hu W, Li M, Li Y, et al. Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer. Cancer Res. 2022;82(21):3903\u201316. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3819.","journal-title":"Cancer Res"},{"issue":"14","key":"2080_CR279","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.3390\/cancers15143649","volume":"15","author":"R Keathley","year":"2023","unstructured":"Keathley R, Kocherginsky M, Davuluri R, Matei D. Integrated multi-omic analysis reveals immunosuppressive phenotype associated with poor outcomes in high-grade serous ovarian cancer. Cancers. 2023;15(14):3649. https:\/\/doi.org\/10.3390\/cancers15143649.","journal-title":"Cancers"},{"key":"2080_CR280","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","volume":"468","author":"D-B Asante","year":"2020","unstructured":"Asante D-B, Calapre L, Ziman M, Meniawy TM, Gray ES. Liquid biopsy in ovarian cancer using Circulating tumor DNA and cells: ready for prime time? Cancer Lett. 2020;468:59\u201371. https:\/\/doi.org\/10.1016\/j.canlet.2019.10.014.","journal-title":"Cancer Lett"},{"issue":"17","key":"2080_CR281","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3390\/diagnostics14171868","volume":"14","author":"A Llueca","year":"2024","unstructured":"Llueca A, Canete-Mota S, Jauregu\u00ed A, Barneo M, Iba\u00f1ez MV, Neef A, et al. The impact of liquid biopsy in advanced ovarian cancer care. Diagnostics. 2024;14(17):1868. https:\/\/doi.org\/10.3390\/diagnostics14171868.","journal-title":"Diagnostics"},{"issue":"24","key":"2080_CR282","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1158\/1078-0432.CCR-23-1197","volume":"29","author":"DN Buckley","year":"2023","unstructured":"Buckley DN, Lewinger JP, Gooden G, Spillman M, Neuman M, Guo XM, et al. OvaPrint-A cell-free DNA methylation liquid biopsy for the risk assessment of high-grade serous ovarian cancer. Clin Cancer Res. 2023;29(24):5196\u2013206. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1197.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2080_CR283","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","volume":"43","author":"Y Hu","year":"2024","unstructured":"Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res. 2024;43(1):23. https:\/\/doi.org\/10.1186\/s13046-024-02949-5.","journal-title":"J Exp Clin Cancer Res"},{"issue":"21","key":"2080_CR284","doi-asserted-by":"publisher","first-page":"11740","DOI":"10.3390\/ijms252111740","volume":"25","author":"A Rossi","year":"2024","unstructured":"Rossi A, Zacchi F, Reni A, Rota M, Palmerio S, Menis J, et al. Progresses and pitfalls of epigenetics in solid tumors clinical trials. Int J Mol Sci. 2024;25(21):11740. https:\/\/doi.org\/10.3390\/ijms252111740.","journal-title":"Int J Mol Sci"},{"key":"2080_CR285","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1017\/erm.2022.32","volume":"24","author":"ST Williams","year":"2022","unstructured":"Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, et al. Precision oncology using ex vivo technology: a step towards individualised cancer care? Expert Rev Mol Med. 2022;24:e39. https:\/\/doi.org\/10.1017\/erm.2022.32.","journal-title":"Expert Rev Mol Med"},{"issue":"2","key":"2080_CR286","doi-asserted-by":"publisher","first-page":"1900100","DOI":"10.1002\/adtp.201900100","volume":"3","author":"AA Popova","year":"2020","unstructured":"Popova AA, Levkin PA. Precision medicine in oncology: in vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy. Adv Ther. 2020;3(2):1900100. https:\/\/doi.org\/10.1002\/adtp.201900100.","journal-title":"Adv Ther"},{"issue":"1","key":"2080_CR287","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022;40(1):26\u201335. https:\/\/doi.org\/10.1016\/j.ccell.2021.12.004.","journal-title":"Cancer Cell"},{"issue":"5","key":"2080_CR288","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1158\/2159-8290.CD-21-1334","volume":"12","author":"J Montero","year":"2022","unstructured":"Montero J, Haq R. Adapted to survive: targeting cancer cells with BH3 mimetics. Cancer Discov. 2022;12(5):1217\u201332. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1334.","journal-title":"Cancer Discov"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02080-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:21:25Z","timestamp":1773832885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02080-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":288,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2080"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02080-6","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}